

World Journal of *Gastroenterology*

World J Gastroenterol 2021 November 14; 27(42): 7210-7401



FRONTIER

- 7210** Frontiers in antibiotic alternatives for *Clostridioides difficile* infection
Phanchana M, Harnvoravongchai P, Wongkuna S, Phetruen T, Phothichaisri W, Panturat S, Pipatthana M, Charoensutthivarakul S, Chankhamhaengdech S, Janvilisri T

OPINION REVIEW

- 7233** Serologic diagnosis of celiac disease: May it be suitable for adults?
Losurdo G, Di Leo M, Santamato E, Arena M, Rendina M, Luigiano C, Ierardi E, Di Leo A
- 7240** Digital surgery for gastroenterological diseases
Hardy NP, Cahill RA

REVIEW

- 7247** Gossip in the gut: Quorum sensing, a new player in the host-microbiota interactions
Coquant G, Aguanno D, Pham S, Grellier N, Thenet S, Carrière V, Grill JP, Seksik P
- 7271** Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic
Sagnelli C, Pisaturo M, Curatolo C, Codella AV, Coppola N, Sagnelli E

MINIREVIEWS

- 7285** Hemostasis testing in patients with liver dysfunction: Advantages and caveats
Nguyen G, Lejeune M, Crichi B, Frere C
- 7299** Colonoscopy-related colonic ischemia
Sadalla S, Lisotti A, Fuccio L, Fusaroli P

ORIGINAL ARTICLE

Basic Study

- 7311** *Fusobacterium nucleatum* colonization is associated with decreased survival of *helicobacter pylori*-positive gastric cancer patients
Hsieh YY, Tung SY, Pan HY, Chang TS, Wei KL, Chen WM, Deng YF, Lu CK, Lai YH, Wu CS, Li C
- 7324** Detailing the ultrastructure's increase of prion protein in pancreatic adenocarcinoma
Bianchini M, Giambelluca MA, Scavuzzo MC, Di Franco G, Guadagni S, Palmeri M, Furbetta N, Gianardi D, Funel N, Ricci C, Gaeta R, Pollina LE, Falcone A, Vivaldi C, Di Candio G, Biagioni F, Busceti CL, Morelli L, Fornai F
- 7340** Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients
Chung MW, Kim MJ, Won EJ, Lee YJ, Yun YW, Cho SB, Joo YE, Hwang JE, Bae WK, Chung IJ, Shin MG, Shin JH

Retrospective Cohort Study

- 7350** Presentation, patterns and predictive value of baseline liver tests on outcomes in COVID-19 patients without chronic liver disease

Bernstein D, Roth N, Kim A, Epstein M, Hirschwerk D, Kvasnovsky CL, Satapathy SK

- 7362** Survival and outcomes for co-infection of chronic hepatitis C with and without cirrhosis and COVID-19: A multicenter retrospective study

Afify S, Eysa B, Hamid FA, Abo-Elazm OM, Edris MA, Maher R, Abdelhalim A, Abdel Ghaffar MM, Omran DA, Shousha HI

Retrospective Study

- 7376** Endoscopic ultrasound features of autoimmune pancreatitis: The typical findings and chronic pancreatitis changes

Zhang SY, Feng YL, Zou L, Wu X, Guo T, Jiang QW, Wang Q, Lai YM, Tang SJ, Yang AM

Observational Study

- 7387** Long-term clinical outcomes of lipiodol marking using standard gastroscopy for image-guided radiotherapy of upper gastrointestinal cancers

Be KH, Khor R, Lim Joon D, Starvaggi B, Chao M, Ng SP, Ng M, Zorron Cheng Tao Pu L, Efthymiou M, Vaughan R, Chandran S

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Fabio Grizzi, PhD, Head, Histology Core, Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano 20089, Milan, Italy. fabio.grizzi@humanitasresearch.it

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Report® cites the 2020 impact factor (IF) for WJG as 5.742; Journal Citation Indicator: 0.79; IF without journal self cites: 5.590; 5-year IF: 5.044; Ranking: 28 among 92 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG's CiteScore for 2020 is 6.9 and Scopus CiteScore rank 2020: Gastroenterology is 19/136.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Ji-Hong Lin*; Production Department Director: *Yun-Jie Ma*; Editorial Office Director: *Ze-Mao Gong*.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski, Subrata Ghosh

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

November 14, 2021

COPYRIGHT

© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Frontiers in antibiotic alternatives for *Clostridioides difficile* infection

Matthew Phanchana, Phurt Harnvoravongchai, Supapit Wongkuna, Tanaporn Phetruen, Wichuda Phothichaisri, Supakan Panturat, Methinee Pipatthana, Sitthivut Charoensutthivarakul, Surang Chankhamhaengdech, Tavan Janvilisri

ORCID number: Matthew Phanchana 0000-0002-7736-7500; Phurt Harnvoravongchai 0000-0001-6730-5712; Supapit Wongkuna 0000-0003-3766-5391; Tanaporn Phetruen 0000-0003-0636-1803; Wichuda Phothichaisri 0000-0003-4056-9923; Supakan Panturat 0000-0003-1012-4499; Methinee Pipatthana 0000-0002-5296-7278; Sitthivut Charoensutthivarakul 0000-0002-4447-3438; Surang Chankhamhaengdech 0000-0002-5414-4072; Tavan Janvilisri 0000-0002-6376-5575.

Author contributions: Phanchana M and Janvilisri T conceptualized and conceived the idea; all authors have been involved equally and have read and approved the final manuscript; Janvilisri T supervised the project.

Conflict-of-interest statement: The authors declare no conflict of interest.

Supported by Research Cluster (Multi-generation Researchers) Grant, Mahidol University, No. MRC-MGR 02/2563.

Country/Territory of origin: Thailand

Specialty type: Microbiology

Peer-review report's scientific quality classification

Grade A (Excellent): A, A

Matthew Phanchana, Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand

Phurt Harnvoravongchai, Surang Chankhamhaengdech, Department of Biology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand

Supapit Wongkuna, Tanaporn Phetruen, Wichuda Phothichaisri, Supakan Panturat, Methinee Pipatthana, Tavan Janvilisri, Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand

Sitthivut Charoensutthivarakul, School of Bioinnovation and Bio-based Product Intelligence, Faculty of Science, Mahidol University, Bangkok 10400, Thailand

Corresponding author: Tavan Janvilisri, PhD, Professor, Department of Biochemistry, Faculty of Science, Mahidol University, 272 Rama VI Road, Thung Phayathai, Ratchathewi, Bangkok 10400, Thailand. tavan.jan@mahidol.ac.th

Abstract

Clostridioides difficile (*C. difficile*) is a gram-positive, anaerobic spore-forming bacterium and a major cause of antibiotic-associated diarrhea. Humans are naturally resistant to *C. difficile* infection (CDI) owing to the protection provided by healthy gut microbiota. When the gut microbiota is disturbed, *C. difficile* can colonize, produce toxins, and manifest clinical symptoms, ranging from asymptomatic diarrhea and colitis to death. Despite the steady-if not rising-prevalence of CDI, it will certainly become more problematic in a world of antibiotic overuse and the post-antibiotic era. *C. difficile* is naturally resistant to most of the currently used antibiotics as it uses multiple resistance mechanisms. Therefore, current CDI treatment regimens are extremely limited to only a few antibiotics, which include vancomycin, fidaxomicin, and metronidazole. Therefore, one of the main challenges experienced by the scientific community is the development of alternative approaches to control and treat CDI. In this Frontier article, we collectively summarize recent advances in alternative treatment approaches for CDI. Over the past few years, several studies have reported on natural product-derived compounds, drug repurposing, high-throughput library screening, phage therapy, and fecal microbiota transplantation. We also include an update on vaccine development, pre- and probiotics for CDI, and toxin antidote approaches. These measures tackle CDI at every stage of disease pathology *via* multiple mechanisms. We also discuss the

Grade B (Very good): 0
 Grade C (Good): 0
 Grade D (Fair): 0
 Grade E (Poor): 0

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Received: March 21, 2021

Peer-review started: March 21, 2021

First decision: April 30, 2021

Revised: May 12, 2021

Accepted: October 25, 2021

Article in press: October 25, 2021

Published online: November 14, 2021

P-Reviewer: Ong LT, Sales-Campos H

S-Editor: Ma YJ

L-Editor: A

P-Editor: Ma YJ



gaps and concerns in these developments. The next epidemic of CDI is not a matter of if but a matter of when. Therefore, being well-equipped with a collection of alternative therapeutics is necessary and should be prioritized.

Key Words: Bacteriophage; Pharmaceutical; *Clostridioides difficile*; Alternative therapy; Drug resistance; Fecal microbiota

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: *Clostridioides difficile* is considered a threat to public health owing to increases in treatment failure over the past few years. Current antibiotic treatment options are highly limited. Therefore, alternative strategies are critical. Herein, we review recent advances in alternative therapeutics, including the development of new chemical entities, fecal microbiota transplantation, pre- and pro-biotic, antitoxin antibodies, use of bacteriophages, and vaccines. We also highlight the concerns, limitations, and directions for each of these developments.

Citation: Phanchana M, Harnvoravongchai P, Wongkuna S, Phetruen T, Phothichaisri W, Panturat S, Pipatthana M, Charoensutthivarakul S, Chankhamhaengdech S, Janvilisri T. Frontiers in antibiotic alternatives for *Clostridioides difficile* infection. *World J Gastroenterol* 2021; 27(42): 7210-7232

URL: <https://www.wjgnet.com/1007-9327/full/v27/i42/7210.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v27.i42.7210>

INTRODUCTION

Clostridioides difficile (*C. difficile*) is a gram-positive, spore-forming, toxin-producing, rod-shaped anaerobic bacterium. *C. difficile* infection (CDI) is a leading cause of nosocomial infections in several countries. The source of *C. difficile* still remains debatable. Studies have proposed that *C. difficile* was part of the human gut commensal bacterial community, as the bacterium could often be isolated from neonates[1,2]. The pathogenicity of *C. difficile* was believed to be attributed to its toxin-production properties; however, recent developments have suggested that outgrowth and colonization are also a pivotal feature of pathogenicity. Under normal conditions, when the gut microbiota is in balance, in a stage called “eubiosis”, *C. difficile* can neither multiply nor colonize the gut, thus preventing it from causing disease. On the other hand, when the composition of the gut microbiota is altered from its normal state, so-called “dysbiosis” occurs, which allows *C. difficile* to multiply and colonize[3,4]. Once colonized, *C. difficile* can produce up to 3 toxins, i.e., toxin A (TcdA), toxin B (TcdB), and binary toxin (CDT). The first two are prominent virulent factors, whilst the latter is controversial[5-7]. The binary toxin is believed to enhance the toxicity and pathogenicity of the primary toxins; however, only a few reports have shown that PCR-negative, but CDT-positive, TcdA and TcdB can cause CDI[8,9]. Details of the pathogenesis of *C. difficile* can be found in reviews elsewhere[5,7,10,11].

CDI is one of the most prominent causes of healthcare-associated infections (HAI). In the United States and European countries, *C. difficile* has been ranked among the top 10 causes of HAI[12]. The challenges of CDI control and prevention are intrinsic drug resistance and environmental resistant spore of *C. difficile*. To date, CDI treatment with most antibiotics has generally resulted in failure. Use of certain antibiotics, such as clindamycin, cephalosporins, quinolones, and penicillins reportedly increased the risk of CDI[13]. Since these antibiotics are broad-spectrum and deplete other gut microbiota that inhibit *C. difficile* multiplication[13], the use of such antibiotics increases CDI risk. To the best of our knowledge, some classes of antibiotics do not increase the risk of CDI, including tetracyclines and aminoglycosides[14]. The antibiotics currently used to treat CDI are vancomycin and fidaxomicin, whereas metronidazole is the antibiotic of choice only when the first two are not available[15]. Along with treatment, prevention is a good control strategy for CDI in most settings. Multiple strategies are being implemented to reduce the rate of CDI, e.g., case management, infrastructure, and antibiotic stewardship, in hospitals[16]. To make all

these control measures meaningful, monitoring of *C. difficile* situations is necessary to ensure that *C. difficile* does not develop resistance to current antibiotics, which would threaten the control and treatment of CDI. There has been an increase in the number of fatal cases of CDI in the past decade[17]. In most countries, a national surveillance system for CDI is still lacking, resulting in under-represented cases of CDI.

Current antibiotic options seem to have reduced efficacy. Recent CDI treatment guidelines have moved away from metronidazole because its efficacy has reduced from 95% pre-2000 to 75% since[15]. A similar reduction has been observed for vancomycin, from 98% to 85%[15]. The increases in recurrent episodes of CDI have reflected the failure of current antibiotics to sustain positive treatment outcomes[18]. Therefore, there is a critical need to develop alternative treatment approaches for CDI (Figure 1). In fact, several alternative approaches are under development, and some are more advanced than others. The development of new antibiotics is the most active research field. Fecal microbiota transplantation (FMT), including pre/probiotic approaches, has also gained extensive research interest in the past few years, as evidenced by several clinical trial registrations. Phage therapy, antitoxin antibody, and vaccines are trying to catch up with others in the league. Notably, there is one antitoxin antibody, bezlotoxumab, approved for preventing the recurrence of *C. difficile* by the United States Food and Drug Administration (FDA), in 2016.

We explored the developments that are currently in the pipeline for alternative therapies by examining data from the ClinicalTrials website. Several trials are investigating current antibiotics for CDI but in various aspects, most commonly in conjunction with FMT or pre/probiotic or antitoxin antibodies. Several molecular entities, such as nitazoxanide, are under investigation. Based on this insight, we extrapolated that the developing treatment options aim to treat/prevent recurrent CDI rather than the initial episode of CDI. Interestingly, currently no trials have been reported on bacteriophage therapy, despite this technology having been active since the early 1990s[19], and its therapeutic application having been demonstrated in other pathogenic bacteria[20]. This indicates that some complexities underline the technology.

SMALL MOLECULES TAKE THE LEAD IN CDI TREATMENT DEVELOPMENT

In the realm of drug discovery and development, small molecules dominate the pharmacy shelf, irrespective of the sources of the small molecules, *e.g.*, natural product-derived/inspired or (semi-)synthetics. According to the United States FDA database, small molecules account for most approved drugs. Regarding the nature and pathogenesis of *C. difficile*, the drugs used to treat CDI have a specific set of requirements, although no target product profiles have been proposed. We believe that the community consensus for the expected properties of the CDI drugs is that they could effectively kill vegetative and spore stages with low systemic absorption (high colonic concentration)[21,22]. Currently in clinical trials, several candidate compounds are being investigated for the development of CDI drugs. Petrosillo *et al*[23] have published a comprehensive review on the development of small molecules for CDI drugs.

Cadazolid is a synthetic oxazolidinone, a derivative of linezolid, which was developed for CDI and also exhibited potency against other enterococci[24]. Cadazolid exhibits good clearance of *C. difficile* with sub-mM MIC and limited effects on other gut microorganisms[25]. Its mechanism of action is protein synthesis inhibition by binding to peptidyl transferase center (PTC). Although cadazolid shares similar mechanism to linezolid, cadazolid is active against linezolid-resistant *C. difficile*[24]. The results from phase 3 clinical trials of cadazolid demonstrated a comparable clinical cure to vancomycin, good safety profile and well tolerated. However, it did not show non-inferiority to vancomycin, which subsequently resulted in the discontinuation of the development by the developer.

Nitazoxanide is an FDA-approved drug with an indication for treatments of cryptosporidiosis and giardiasis. At the millimolar range, this drug inhibited multiple gram-negative and gram-positive anaerobic bacteria, *e.g.*, *Bacteroides* spp., *Prevotella* spp., *C. difficile*, *C. perfringens* and *Mycobacterium tuberculosis*[26]. The mechanism of action of nitazoxanide has been suggested to involve the inhibition of pyruvate ferredoxin oxidoreductase (PFOR) in anaerobic energy metabolism[27] and the disruption of membrane potential in aerobic bacteria[28]. In addition, studies have shown that nitazoxanide is effective against various RNA and DNA viruses including coronavirus




Figure 1 Alternative approaches for *Clostridioides difficile* infection treatment under development. Different approaches are aiming at the different pathological stages of *Clostridioides difficile* (*C. difficile*) infection. Small molecule and natural product derived have broad range activity from vegetative cell inhibition to biofilm and spore effects. Bacteriophage therapy affects mostly the vegetative stage of *C. difficile*. Fecal microbiota transplantation and pre- and probiotics aim to restore the balance of the gut microbiota mitigating the chance of *C. difficile* population and production of toxins. Vaccine and antitoxin antibody are targeting toxin neutralization.

[29] and SARS-CoV-2[30]. The result of an early phase-3 trial have suggested that the effectiveness of nitazoxanide is comparable to that of vancomycin, although noninferiority to vancomycin is inconclusive owing to small sample size and early termination[31]. Hence, the mechanism of action of nitazoxanide compared with current CDI treatments is anticipated from other ongoing trials because of the high expectations for nitazoxanide in the treatment of recurrent CDI[32].

Ridinilazole (SMT19969) is an antibiotic developed specifically for CDI. It exhibits good anticlostridial activity, with different magnitude, against multiple *Clostridium* spp. and also *C. difficile* with minimal effect to other gut microbiome[33,34] and bile acid profiles[35]. The mechanism of action of ridinilazole is believed to be unique from that of other drugs. It does not interfere with cell division by inhibiting cell wall synthesis; it does so by decreasing septum formation[36]. Ridinilazole has a low systemic absorption and, therefore, has a high colonic concentration, making it a good agent for CDI treatment[34]. The results obtained from a phase-2 clinical trial demonstrated sustained clinical response with ridinilazole treatment, noninferiority over vancomycin, and good tolerance[37]. These results altogether support further development of ridinilazole for clinical use. Phase-3 clinical trials are ongoing.

Advancements in technology and compound libraries has helped considerably in screening thousands of compounds, and has been made possible within a much shorter time. In the past few decades, several FDA-approved drugs were initially screened from large compound libraries through phenotypic screening[38]. A recent analysis showed that more than 16 million compounds can be purchased from various chemical suppliers[39]. This extends our opportunity to discover even more hits for drug discovery and development.

Apart from a rationally designed drug approach or large library screening, one recent popular drug development approach is drug repurposing or repositioning. The approach is regarded as a shortcut for a lengthy conventional drug development pipeline, as safety and pharmacokinetic data are readily available, which allows the compounds to proceed directly into clinical trials. Many works have demonstrated approved drugs can be repurposed for *C. difficile*[40,41]. The screening of both random compound libraries and approved drugs has become a very intriguing approach for drug development in the past years. Several studies conducted using this approach have been published[30,40,41]. However, if the route of administration is different from the approved indication, preclinical stages are necessary to evaluate the safety profile[42].

We examined the molecular similarity among the FDA-approved drugs from screening campaigns mentioned in this paper[40,43]. Molecular clustering of these drugs will help us predict a key biomolecular pathway or target the hits interact with or act upon. Molecular analysis was performed using the KNIME Analytics Platform, free and open-source software, aiming to solve large-data analysis problems[44]. KNIME offers an extensive toolset for data pre-processing and transformation as well as visualization and it can be equipped with extensions and nodes that are suitable for pharmaceutical research. We employed KNIME 4.1.2 equipped with various extensions, including RDKit KNIME integration, KNIME Distance Matrix Extension, and KNIME-CDK to create our workflow[45,46]. The workflow of the molecular analysis of the hits is shown in Scheme 1 of the supplement file.

The results shown in Table 1 and Supplementary material revealed that those hits can be categorized structurally into two large clusters and six smaller clusters based on molecular clustering analysis (> 3 hits per cluster). The largest group of clusters belongs to the β -lactam antibiotics (clusters 88–97, Supplementary material in SI) and the second largest is the tetracycline and its derivatives (clusters 98–99, Supplementary material in SI). Although these drugs are well-known antibiotics and are expected to exert some biological activity against *C. difficile*, the clinical use of these materials might not be of best interest since they are broad-spectrum antibiotics that could cause concern in gut microbiota dysbiosis and may drive an undesired side-effect of antibiotic resistance elsewhere in the body[47]. Other known antibiotics, such as aminoglycosides (cluster 123) and benzalkoniums cationic surfactant (cluster 61) which could be used topically as antiseptic were also identified.

Interestingly, metronidazole, one of the current treatments for *C. difficile*, and its derivatives (cluster 42) also show up as one cluster. Further exploration in this chemical moiety seems a way forward to avoid cross-resistance with current antibiotics as the drugs within this class exert their biological activity through the formation of nitroso radical. The mechanism that causes microbial DNA damage is not related to a certain enzyme and, therefore, makes it more challenging for the bacteria to develop resistance. Antifungal imidazoles were identified in another interesting cluster (cluster 21). These drugs act as an inhibitor of lanosterol 14 α -demethylase, which catalyzes the formation of ergosterol, an important sterol found in eukaryotic cell membranes[48]. Although the mechanism of this class of drugs in *C. difficile* is not known, the result may prompt scientists to investigate the potential of these materials further, since these azoles are not currently in use as antibiotics, and it could avoid unwanted antibiotic cross-resistance with other current drugs[40,43]. Furthermore, most of the drugs identified from the FDA-approved panels resulted in drugs with anthelmintic (parasitic) indication[40]. It is possible that these parasites share a similar anaerobic/microaerophilic environment, and to some extent anaerobic metabolism, to that of *C. difficile*, thereby allowing those drugs to be active against *C. difficile*. It would be very interesting to observe whether this hypothesis remains valid when more screenings are performed. Although several drugs and lead compounds have been identified in the literature, only a few have been put forward into the development pipeline. This is largely due to the lack of academic and industrial partnerships. We have seen what the scientific community has achieved, in an unprecedented time scale, with the development of COVID-19 vaccines with the leading role of big pharmaceutical companies and their academic partners. This emphasizes the importance of academic-industrial partnerships in drug and vaccine developments, as this field of research is resource-intensive and requires considerable funding and workforce. Nevertheless, non-profit organizations can play an important role in drug discovery and development as well evidenced by the approval of anti-tubercular pretomanid, which was led by the TB Alliance[49].

Table 1 Representatives of anti-*Clostridioides difficile* chemical clusters from reported literature

Cluster No.	Compound class
21	Antifungal imidazoles
42	Metronidazole and its derivatives
61	Benzalkonium cationic surfactants
88–97	β -lactams
98–99	Tetracycline and its derivatives
123	Aminoglycosides

NATURAL PRODUCTS SERVE AS A GOOD SOURCE OF ANTI-CLOSTRIDIAL ACTIVITIES

Humans have been using natural products as traditional medicine for treating several illnesses for centuries. It has been estimated that approximately 500000 plant species exist on the planet, but only 1% of them have been explored for bioactive compounds [50]. A detailed analysis of FDA-approved drugs from 1931 to 2013 revealed that natural products and their derivatives represented over 30% of new drugs[51]. Due to the increasing prevalence of antibiotic resistance in several pathogenic bacteria, the prescribed antibiotics may no longer be effective. Therefore, exploration of plant-derived compounds could provide us a tremendous opportunity to discover novel bioactive agents.

Several plant extracts and plant-derived compounds possess antibacterial activity against *C. difficile* and their action has been investigated previously. Roshan *et al*[52] reported the anti-*C. difficile* activities of natural products that are commercially available as both processed and unprocessed products. Some processed products such as aloe vera gel, peppermint oil, artichoke capsules, and garlic tablets demonstrated antimicrobial activity against *C. difficile* with MICs of 16% (v/v), 8% (v/v), 75–150 mg/mL, and 37.5–75 mg/mL, respectively[52]. Regarding the unprocessed products, allicin (derived from garlic) and cinnamon powder demonstrated antimicrobial activity against *C. difficile* with MICs of 2.3–4.7 and 75 mg/mL, respectively. Zingerone (derived from ginger) and menthol (derived from peppermint) inhibited *C. difficile* at the same inhibition concentration of 9.4 mg/mL, whereas trans-cinnamaldehyde, an active constituent found in cinnamon bark, exhibited strong inhibitory activity with an MIC of 0.2 mg/mL[52]. δ -3-Carene, a monoterpene derived from the root of *Asarum heterotropoides*, exhibited anticlostridial activity with an MIC of 0.7 mg/mL with a less potential of suppressing beneficial intestinal bacteria[53]. Moreover, an essential oil extract that contains 16.5% of δ -3-carene exhibited antimicrobial activity against *C. difficile* at a concentration of 0.25% (v/v)[54]. Xanthohumol, derived from *Humulus lupulus* L., exhibited anti-*C. difficile* activity with MICs of 0.032–0.107 mg/mL against 28 different *C. difficile* isolates[55]. Crude methanol extract of the bark of *Mammea africana* demonstrated anti-*C. difficile* activity with an MIC of 2 μ g/mL. The identified active flavonic compound in *M. africana*, mammeisin or mammea A/AA, exhibited strong inhibitory activity with an MIC of 0.25 μ g/mL[56]. Curcumin (phenol), an active agent derived from *Curcuma longa*, is reportedly active against 27 *C. difficile* strains, with MICs ranging between 16 and 32 μ g/mL. The inhibition was specific to *C. difficile* as it did not affect beneficial gut microbiota[57]. Curcumin was also able to reduce sporulation and toxin production in *C. difficile*[57].

Several studies have reported that the anticlostridial activity of crude plant extracts contain unidentified active compounds. For instance, pomegranate extract was shown to exhibit specific inhibitory activity against 23 tested isolates of *C. difficile* with MICs of 12.5–25 μ g/mL, but no inhibitory effect was observed on the tested normal intestinal bacteria (MIC > 400 μ g/mL)[58]. Investigation of a commercial animal supplement, BIOCITRO, a citrus fruit extract, revealed an inhibitory effect on *C. difficile* with MICs of 16–32 μ g/mL with a possible mode of action of disrupting polysaccharides and carbohydrates of the cell wall[59]. In addition, methanolic extract of the leaf and rhizomes of *Aristolochia paucineris* Pomel demonstrated an inhibitory effect on *C. difficile*, with concentrations ranging from 8 to 64 μ g/mL[60].

Several compounds are known to kill *C. difficile* through changes in cell permeability. The ability of membrane disruption was suggested for zingerone, menthol, and trans-cinnamaldehyde[61]. Asiatic acid, an active triterpenoid derived

from *Centella asiatica*, exhibited significant antimicrobial activity against *C. difficile* strains isolated from different sources by disrupting the cytoplasmic membrane with MICs of 10–20 µg/mL[62]. Lauric acid, an active component found in virgin coconut oil, exhibited anticlostridial activity at a 250-µmol/L concentration through the membrane disruption mechanism[63]. Cannabidiol, an active ingredient derived from cannabis, could inhibit *C. difficile* at concentrations of 2–4 µg/mL, possibly by disrupting the bacterial membrane[64]. Another study of cannabidiol in caco-2 cells infected with *C. difficile* reported its potential to inhibit toxin A-induced cytotoxicity [65]. Interestingly, data analysis of hospitalization from the Healthcare Cost and Utilization Project in 2014 suggested that patients associated with cannabis usage had potentially lower risk for CDI by 28%[66].

The dormant spores of *C. difficile* contribute to transmission and link with the pathogenesis of CDI. *C. difficile* spores can persist in harsh conditions. They can then translocate to the intestinal tract, germinate in response to specific bile salts, and initiate infection. Most antibiotics are inactive against *C. difficile* spores because of the spores' intrinsic durability. In addition to vegetative cell activity, natural products are active against several spore stages of *C. difficile*. Peppermint oil and trans-cinnamaldehyde have been shown to exhibit sporocidal activity, which reduces the number of spores by up to 200 times when spores were exposed for 7 d[67]. Several compounds such as allicin and carvacrol, essential oils found in oregano, and fresh onion bulb extracts could inhibit spore outgrowth[67,68]. As *C. difficile* spores play an essential role in CDI, the inhibition of sporulation is an attractive strategy to reduce infection. A study conducted by Roshan *et al*[67] showed that the subinhibitory concentration of coconut oil, fresh onion bulb, and fresh ginger can reduce the number of spores production by 90%. Another study conducted on Manuka honey or Leptospermum honey also reported the inhibition of sporulation in *C. difficile*[69]. Baicalin, a flavonoid derivative present in the root of *Scutellaria baicalensis*, could inhibit both sporulation and outgrowth of *C. difficile* at a concentration of 1.6 mmol/L. It also reduced toxin production by downregulating *tcdA* and *tcdB* gene expression[70]. Toxin A and toxin B produced by *C. difficile* are cytotoxic and cause colitis. Leptospermum honey, fresh onion bulb, and trans-cinnamaldehyde were able to reduce the cytotoxicity of *C. difficile* toxins in Vero cells by 70% and toxin production by 40%[71].

In an *in vivo* mouse model, it was observed that berberine, a compound derived from the genus *Berberis*, has the potential to prevent recurrent CDI and restore gut community, either alone or in combination with vancomycin[72]. It is noteworthy that successful therapy by endoscopic lavage with Manuka honey was reported in the patient with vancomycin treatment failure[73].

ANTITOXIN ANTIBODIES WITH ANTIBIOTICS IMPROVE TREATMENT SUSTAINABILITY

Toxin production has long been associated with CDI pathogenicity. Classical antibiotic treatments effectively eliminate the pathogen, although they inevitably affect the normal gut microbiota to some extent. Antitoxin antibody treatment aims to neutralize the toxicity of the toxin, rather than interfere directly with the bacterium. Therefore, it can reduce clinical severity, in conjunction with antibiotic treatment, and reduce recurrent CDI. To date, the only FDA-approved antitoxin antibody for CDI treatment is bezlotoxumab, a human monoclonal antibody against toxin B. A detailed study demonstrated that bezlotoxumab binds to carbohydrate-binding pockets on toxin B, which directly prevents the interaction between the toxin and host cells[74]. This hypothesis was supported by a mutant antibody that does not bind to Fc receptors of host immune cells, which provides similar toxin neutralization and protection effects as wild-type antibody[75]. Its toxin A counterpart, actoxumab, did not demonstrate improvement in clinical efficacy, and therefore it was discontinued during the phase 3 trial[76]. These results support the hypothesis that TcdB is a more prominent virulent factor than other toxins and that the interplay between these toxins is a complex process.

IM-01 is an experimental polyclonal antibody for inflammatory bowel disease, including Crohn's disease, and CDI. IM-01 is produced using a chicken egg technique by immunizing hens with toxin A, toxin B, and *C. difficile* spores. Currently, detailed information on this intervention is lacking, but its phase 2 clinical trial is being recruited. The results from patent filing showed good antibody production, toxin neutralization, reduction of spore burden, and inhibition of vegetative cell growth[77]. These results indicate that IM-01 is a promising development for CDI treatment;

however, it is too early to state whether it would work effectively independently or in combination with antibiotics.

Colostrum is a fluid produced by the mammary glands immediately after the birth of a newborn. It has been demonstrated that cows persistently injected with antigens will produce antibodies in the colostrum, which are collectively referred to as hyperimmune bovine colostrum (HBC). A preclinical piglet model study showed that HBC can reduce the severity of CDI[78]. A limitation of using colostrum is the scale of production, which is limited to a few hours after birth. Therefore, some studies have examined the use of milk or whey protein isolate (WPI) instead of colostrum for CDI treatment. WPI exhibited superior and sustained treatment outcome compared with vancomycin in a hamster model[79]. Considering its clinical use, we found only one terminated phase 2 trial, which was completed, but there were no results, of the whey protein concentrate MucoMilk.

Altogether, antitoxin antibodies in any form appear to be a significant candidate for alternative treatment of CDI, since preclinical studies have demonstrated good inhibition of vegetative cells and spores and neutralization effect of toxins in initial and recurrent episodes of CDI. Nonetheless, it will take some time to observe this group of treatments for clinical use, as production is more complicated and potentially expensive.

FECAL MICROBIOTA TRANSPLANT IS A VERY ATTRACTIVE APPROACH FOR CDI

Although antibiotic administration is the first-line treatment for CDI, severe outbreaks and recurrent episodes remain excessive due to a significant increase in resistant strains[80]. Treatment options for CDI, especially recurrent CDI, become limited, due to which the development of alternative therapeutics is highly required. In particular, CDI develops when the indigenous microbiota is dysbiotic, typically *via* exposure to antibiotics, thereby allowing *C. difficile* to acquire nutrient niches in the gut and cause disease[13,81]. Based on this concept, restoration of the healthy microbial community, eubiosis, can help eliminate and prevent this growing problem. To date, researchers have expressed interest in biotherapeutic strategies that confer curative effects on recurrences. A burgeoning alternative treatment approach for recurrent CDI is FMT, which refers to the administration of feces collected from a healthy individual to the intestinal tract of a patient[82,83]. In general, FMT is applied to a patient with refractory CDI who had failed standard antibiotic treatments in an initial episode of CDI[84]. This approach emerged due to its unique feature, restoring the balance of the gut microbiota, which is unlikely to be achieved by other approaches. FMT provides multiple mechanisms of colonization resistance, such as competition for nutrients, production of antimicrobial peptides, and production of short-chain fatty acids (SCFAs) to inhibit vegetative growth and spore germination of *C. difficile*[85,86].

The first clinical trial of FMT, whose efficacy was significantly greater than the use of antibiotics for recurrent CDI treatment, was performed by van Nood *et al*[87] and published in 2013. Among the 16 patients, 13 with FMT recovered from CDI after the first infusion and the symptoms of 2 patients resolved after a second infusion, whereas only 3 of 13 patients resolved with vancomycin treatment alone. Other clinical studies have demonstrated that FMT provides better benefits than standard antibiotics for treating recurrent CDI by replenishing the balance of the gut microbiota. Currently, clinical studies are ongoing with the recruitment of patients with relapsing CDI to evaluate the safety and efficacy of FMT (Table 2). The upper and lower route of administration has been used in delivering the transplant. Several methods, including nasoduodenal, enema, upper endoscopy, colonoscopy, and oral capsules, are commonly used for administering FMT, with diverse outcomes[88]. A study using colonoscopy demonstrated the resolution of CDI in 18 of 20 patients treated with FMT compared with 5 of 19 patients treated with vancomycin[89]. Conversely, FMT administered by enema was found to have a low success rate in treating acute episodes of recurrent CDI[90]. To simplify administration, oral capsules of fecal filtrates have been developed and widely used. Patients with relapsing CDI had a decent response to FMT administered by oral capsules, wherein the resolution rate of recurrent CDI was similar to that observed with colonoscopy[91]. These findings demonstrated no definite preference of the administration route for FMT.

Another factor questioned in FMT is the preparation of fecal material. Initially, fresh stools from donors were used for infusion. As the process of collecting fresh stools is difficult, frozen and lyophilized stools were then considered for transplant delivery.

Table 2 Recent clinical trials examining potential fecal microbiota transplantation for treatment of *Clostridioides difficile* infection

Current phase	Title	ClinicalTrials.gov Identifier	First posted
NA	Fecal microbiota transplantation for <i>C. difficile</i> infection	NCT01905709	July 23, 2013
	Immune response to FMT for <i>C. difficile</i>	NCT02797288	June 13, 2016
	Outcomes and data collection for fecal microbiota transplantation for the treatment of recurrent <i>C. difficile</i>	NCT03562741	June 19, 2018
	Fecal microbiota transplantation (FMT) for <i>C. difficile</i> (CEFTA)	NCT03712722	October 1, 2018
	Rescue fecal microbiota transplantation for national refractory intestinal infection	NCT03895593	March 29, 2019
	Safety and efficacy of fecal microbiota transplantation	NCT04014413	July 10, 2019
1	Fecal transplant for pediatric patients who have recurrent <i>C. difficile</i> infection (FMT)	NCT02134392	May 9, 2014
2	Stool transplants to treat refractory <i>C. difficile</i>	NCT02127398	April 30, 2014
	FMT versus antimicrobials for initial treatment of recurrent CDI	NCT02255305	October 2, 2014
	Fecal microbiota therapy for recurrent <i>C. difficile</i> infection	NCT02686645	February 19, 2016
	Phase II trial of fecal microbiota transplant (FMT) for VRE and CRE patients	NCT03643887	August 23, 2018
	Fecal microbiota transplantation (FMT) plus fidaxomicin for severe or fulminant <i>C. difficile</i>	NCT03760484	November 30, 2018
	Multicentre blinded comparison of lyophilized sterile fecal filtrate to lyophilized fecal microbiota transplant in recurrent <i>C. difficile</i> infection	NCT03806803	January 16, 2019
	FMT and bezlotoxumab compared to FMT and placebo for patients with IBD and CDI (ICON-2)	NCT03829475	February 4, 2019
	PMT for severe-CDI	NCT03970200	May 31, 2019
	Penn microbiome therapy (PMT) for recurrent <i>C. difficile</i> infection	NCT03973697	June 4, 2019
	Fecal transplantation for primary <i>C. difficile</i> infection (COLONIZE)	NCT03796650	January 8, 2019
3	Microbiota restoration therapy for recurrent <i>C. difficile</i> infection (PUNCH CD3-OLS) (CD3-OLS)	NCT03931941	April 30, 2019
	Fecal microbiota transplantation for primary <i>C. difficile</i> diarrhea	NCT02801656	June 16, 2016

FMT: Fecal microbiota transplantation; *C. difficile*: *Clostridioides difficile*; PMT: Penn microbiome therapy.

Several clinical trials claimed that frozen stool was comparable to fresh stool with no loss of effectiveness[92,93]. In contrast, lyophilization reduced the efficacy of the transplant material compared with fresh and frozen materials[94]. In particular, frozen fecal material is becoming available for commercial purchase. In addition to its use for treating multiple episodes of recurrent CDI, FMT has been proposed as a promising treatment approach for severe and complicated CDI. Evidence obtained from clinical trials has shown that FMT improved survival in severe cases, including immunocompromised patients[95,96].

Although FMT is a favorable therapeutic option for recurrent CDI, a major concern is that there is no universal or industrial standard such as a defined bacterial formula; moreover, there is no information on the mechanism associated with FMT-screening methods for adverse transmission events and the period of treatment[97,98]. Such limitations of FMT led to the discovery of beneficial microorganisms in fecal materials that activate colonization resistance and the determination of their roles in inhibiting *C. difficile*. Correspondingly, the refined stool-derived microbial suspension RBX2660 has been successfully used to treat relapsing CDI, and is currently under a phase 2b study[99]; furthermore, SER-109 and SER-262, defined microbial preparations containing spore-forming bacteria purified from human feces and formulated as a capsule, are currently being investigated in a phase 3 and 1b trial[100,101]. These data conclude that FMT continues to be a recommended therapy for recurrent CDI, and in the meantime, a number of studies continue identifying essential bacteria species from the feces of healthy donors to formulate standard microbial preparations approved by the FDA.

Another point of concern for FMT is the unintentional transfer of drug-resistant bacteria, which could possibly lead to complicated infection and death. There have been multiple bacteremia incidents in patients who received FMT[102], some of which were severe and life-threatening. This indicates the need for a standardized protocol for stool preparation, to minimize potential drug-resistant bacterial infection from FMT, including, but not limited to, extended-spectrum beta-lactamase (EBSL)-producing *E. coli*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *etc.*[103]. Recently, a caution has been issued regarding the transmission of SARS-CoV-2 in FMT[104].

PROBIOTICS AND PROBIOTIC PROMOTE GUT BALANCING

Probiotics are live microorganisms that confer health benefits on the host when administered in adequate amounts[105,106]. They can improve host immunity by producing beneficial metabolites, such as SCFAs, as well as preventing enteric infections *via* colonization resistance mechanisms, such as competition for nutrients, inhibition of bile acid conversion, and production of antimicrobial peptides[107,108]. Numerous probiotic strains and probiotic mixtures have been evaluated to combat CDI in *in vitro* studies; however, there are limitations due to the lack of evidence from human clinical trials.

Lactobacillus rhamnosus GG and *Saccharomyces boulardii*, the most common probiotics, have provided promising applications against CDI and have been widely investigated in clinical trials. The efficacy of *S. boulardii* in CDI management was first examined by McFarland *et al*[109], who reported a significant reduction in recurrence rates after the administration of *S. boulardii* twice a day for 4 wk during and after antibiotic treatment. Their study demonstrated a significant reduction in the CDI recurrence rate in the *S. boulardii* treatment group compared with the placebo group. Moreover, patients with relapsing CDI had a statistically significant response to *S. boulardii* compared with placebo. The probiotic effect of *L. rhamnosus* GG in a clinical study was first verified by Gorbach *et al*[110], in 1987. They successfully used the organism to treat 5 patients with multiple recurrent CDI episodes. In addition to its beneficial effects in treating refractory CDI, *L. rhamnosus* GG displayed a protective potential in healthy individuals[111]. Further meta-analytical studies have been performed to confirm the usefulness of *S. boulardii* and *L. rhamnosus* GG in the prevention of CDI [112,113]. In addition to single-probiotic strains, probiotic mixtures have been developed for quite some time. The probiotic mixture BioK+ containing *L. acidophilus* CL1285, *L. rhamnosus* CL2, and *L. casei* LBC80R was able successfully to reduce the CDI rate from 18.0 to 2.3 cases per 10000 patients. Furthermore, new mixtures have been developed and are in the process of clinical trials[114]. The probiotic mixture of *L. casei* DN-114 001, *S. thermophilus*, and *L. bulgaricus* was randomly administered to hospital inpatients twice-daily during, and for 1 wk after, antibiotic treatment[115]. This probiotic mixture showed a positive result, wherein no individual in the probiotic group developed CDI compared with 9 of 53 individuals who contracted CDI in the placebo group. Another study evaluated the efficacy of the probiotic mixture of *L. acidophilus* and *L. casei*[116]. The probiotic doses were varied and administered within 1.5 d of initial antibiotic therapy and then continued for 5 d after the final antibiotic dose. Both higher dose and lower dose probiotic groups showed significantly reduced CDI incidence rates, at 1.2% and 9.4%, respectively, compared with 23.8% in the placebo group. The most recent clinical trial of a multi-strain probiotic consisting of *L. acidophilus* NCFM, ATCC700396, *L. paracasei* Lcp-37, ATCC SD5275, *Bifidobacterium lactis* Bi-07, ATCC SC5220, and *B. lactis* B1-04, ATCC SD5219 has been conducted[117]. A phase 2 study evaluated the potential benefits of this probiotic mixture by administration daily for 4 wk. The results revealed a shorter duration of diarrhea in patients with an initial episode of mild-to-moderate CDI compared with the placebo group. Based on the available evidence, probiotics are strongly advocated as an alternative for preventing and treating CDI. However, the high heterogeneity in existing studies indicates that the beneficial effects of probiotics are rather subjective[118]. Therefore, discovering novel probiotics and understanding their functions and interactions have been continuing to improve the probiotic effects in a clinical setting.

It is known that diet has a key influence on the composition and functions of the gut microbiota[119]. Several types of fiber, particularly, galacto-oligosaccharides (GOS) and fructo-oligosaccharides (FOS), have been found to increase the abundance of common probiotic bacteria, such as *Bifidobacterium* and *Lactobacillus* species[120]. Hence, plant-based foods containing dietary fiber are generally accepted as favorable for gut health. Certain fiber types, including FOS, GOS, and inulin, are considered to

be prebiotics, which are defined as substrates that are selectively used by host microorganisms conferring a health benefit[121]. The combination of probiotics and prebiotics has been proposed as an alternative, known as synbiotics, to prevent and treat refractory CDI. A recent study investigated the effects of a synbiotic, *L. plantarum* DSM 21379 and xylitol, on the germination of *C. difficile* spores[122]. *In vitro* experiments demonstrated that the synbiotic completely inhibited the germination of *C. difficile* spores. Moreover, the administration of this synbiotic for 5–6 d before ampicillin and *C. difficile* challenge in mice reduced the CDI incidence from 44% to 22% mortality. Another *in vitro* study examined the inhibitory capability of four different *Bifidobacterium* sp. strains combined with various prebiotics against *C. difficile* growth. Using oligo-fructosaccharides as a carbon source, it was observed that *B. longum* and *B. breve* rescued the survival of a cell line exposed to *C. difficile* cell-free supernatant. These findings indicate that a probiotic strain requires a specific prebiotic substrate. To produce more effective synbiotics to control CDI, it is necessary to determine the optimal prebiotic for each probiotic.

BACTERIOPHAGE AND ITS PRODUCTS SPECIFICALLY ELIMINATE *C. DIFFICILE*

As bacteria-infecting viruses, bacteriophages or phages have received attention for potential use as an alternative treatment for several bacterial infections. The high specificity to their bacterial hosts and the self-replicating mechanism of phages are claimed to have advantages over other approaches. Although *C. difficile* phages have been discovered and investigated since 1983[123], the use of phages for human infection is restricted due to some limitations. The key bacteriophage studies of *C. difficile* are summarized in Table 3.

C. difficile phages were first described for bacterial typing purposes[123]. Morphological analysis showed that most of them are either *Myoviridae* or *Siphoviridae*, belonging to the order *Caudovirales*. They possess dsDNA as their genetic materials [124,125]. Currently, all 26 complete genomes of *C. difficile* phages are characterized as temperate; they can alternate their life cycles between lytic and lysogenic cycles[126, 127]. This is a major constraint, as most therapeutic phage applications require a virulent phage, *i.e.*, a phage with a strictly lytic life cycle. Therefore, current research has been focusing on the use of temperate phage and phage-derived proteins to combat CDI[128–131]. At the very beginning, phage therapy was performed as a single-phage treatment to ensure its capacity. It has been demonstrated that phiCD27 significantly reduced the growth of *C. difficile* cells, as well as the production of toxin A and toxin B in an *in vitro* batch fermentation and artificial gut model. Furthermore, phiCD27 treatment did not affect commensal microbiota in both models, suggesting high specificity on the bacterial target[132]. However, using only one phage has some limitations due to narrow host range and lysogenic capacity. Therefore, a combination of different phages or phage cocktails has become more intriguing[133–135].

A phage cocktail was successfully developed both *in vitro* and *in vivo*, as observed in the study conducted by Nale *et al*[134]. Optimized cocktails of phiCDHM1 to phiCDHM6 and phiCDHS1 were tested against *C. difficile* ribotypes 076, 014/020, and 027 strains. The best combination included phiCDHM 1, 2, 4, and 6, which could completely kill *C. difficile* without regrowth. The CDI hamster model showed a significantly lower number of spores in the cecum and colon with the combination of phiCDHM 1, 2, 5, and 6. The same phage mixture was used in the wax moth larva *Galleria mellonella*. The efficiency of using phage combined with antibiotics, including vancomycin and clindamycin, was evaluated. The results suggested that phage could be used as a supplement to antibiotic treatment and prevent the onset of CDI. Prophylaxis was the most effective therapy with 100% protection, and efficiency was reduced when used as a remedial treatment. Moreover, the authors found that the phage could penetrate and prevent biofilm formation in the *C. difficile* ribotype 014/020[136]. Phage treatment in an artificial gut model was further investigated using these sets of phage combinations. A six-log reduction in *C. difficile* growth was observed after 5 h in the prophylaxis group, and the vegetative cells were completely removed within 24 h[136]. Furthermore, metagenomic analysis was conducted using fecal samples of volunteers to observe the impact of phage therapy on the total gut microbiome. Another *in vitro* study conducted on the human colonic cell line HT-29, which is the CDI site, reported that phiCDHS1 preferentially adsorbed onto HT-29 cells, thereby promoting the interaction between the phage and bacterial cells[137]. It has also been shown that either bacterial lysis by phage or the phage itself was

Table 3 Key experiments in bacteriophage for *Clostridioides difficile* infection treatment

Phage	Experiment	Finding	Ref.
phiCD140	A single dose of phage treatment for <i>C. difficile</i> infection in hamsters	Surviving of phage treated hamster	[135]
phiCD27	Phage treatment of CDI in an <i>in vitro</i> batch fermentation and human colon model	(1) Reduction of both vegetative cell and toxin A and toxin B productions from <i>C. difficile</i> ; and (2) No impact on others gut microbes	[135]
phiCDHM1 to phiCDHM6, and phiCDHS1	(1) Investigation for an effective phage combination; and (2) Phage delivered orally in hamster model every 8 h after <i>C. difficile</i> challenge	(1) Discovery of phage-resistant colonies after a single phage treatment; and (2) Reduction of <i>C. difficile</i> amount and colonization using phage combination <i>in vivo</i>	[124]
phiCDHM1, 2, 5, and 6	(1) Phage treatment before and after the biofilm formation; (2) First time using <i>Galleria mellonella</i> (wax moth) model for <i>C. difficile</i> phage; and (3) Using phage in combination with antibiotics (vancomycin)	(1) Reduction and prevention of the biofilm establishment <i>in vitro</i> ; and (2) Disease prevention in the prophylaxis group and increasing the wax moth survival rates	[130]
phiCDHM1, 2, 5, and 6	(1) Optimized temperate phage cocktail to treat in batch fermentation model; and (2) First metagenomic analysis of phage treatment on gut microbiome	(1) <i>C. difficile</i> elimination after 24 h in prophylactic condition while maintain other microbiota components; and (2) No significant impact on other bacterial groups in human gut	[127]
phiCDHS1	Measurement of planktonic and adhered <i>C. difficile</i> cells and free phage to human colon tumorigenic cell line HT-29	(1) Reduction of planktonic and adhered <i>C. difficile</i> ; and (2) No cytotoxicity to human cells	[129]
phiCD24-2	(1) Using engineered phage delivered Type 1-B CRISPR system as antimicrobial agent <i>in vitro</i> and <i>in vivo</i> ; and (2) Mutation of phage lysogenic gene by the <i>cl</i> repressor and integrase gene deletion	(1) <i>C. difficile</i> eradication effectively in engineered phage comparing with wild-type phage; and (2) Detection of lysogen due to potentially functional complements from <i>C. difficile</i> prophage	[125]

C. difficile: *Clostridioides difficile*.

nontoxic to the colonic cells.

Recently, phiCD24-2 has been engineered to contain a genome targeting CRISPR-Cas3, which is commonly found in the genome of *C. difficile*[135]. The major characteristics of the engineered phage or CRISPR-enhanced phage (crPhage) have been investigated. There was no difference in phage morphology or host range compared with the wild-type phage (wtPhage). The efficiency of phage treatment for *C. difficile* was determined both *in vitro* and *in vivo*. crPhage demonstrated a higher efficiency to reduce the growth of vegetative cells than wtPhage in both models. However, the bacterial number rebounded by 24 h, suggesting lysogination into the host genome rather than bacterial lysis. The mouse model exhibited a significant difference in the number of *C. difficile* cells recovered from mouse feces between wtPhage and crPhage treatments, indicating the superiority of crPhage treatment *in vivo*. The CRISPR approach enhances phage efficiency during the lytic cycle as bacterial lysis can occur *via* two independent mechanisms, including genome damage and phage lytic activity *via* endolysin and holin expression. The challenge of engineered phages remains due to lysogenic conversion. Therefore, the removal of *cl* repressor and integrase genes was performed to generate lysogenic phage mutants[135]. Although lysogen from *in vitro* culture was not detected, it was detectable in mouse feces. These findings suggested the functional complement in the *C. difficile* genome for those removed genes.

An alternative to using temperate phages for therapeutic purposes is to utilize their products. Endolysin, a peptidoglycan hydrolase enzyme, is encoded by the phage genome. Endolysin is required to disrupt the bacterial cell wall to release phage progeny at the final step of viral infection. The endolysin CD27L is derived from the phage CD27, which is the first phage endolysin characterized in *C. difficile*. The specificity test demonstrated that CD27L was active against a panel of 30 *C. difficile* strains, including a hypervirulent ribotype 027[125]. The N-terminal truncated CD27L, CD27L₁₋₁₇₉, improved the lytic activity when tested against *C. difficile*. CD27L₁₋₁₇₉ exhibited a slightly broader lytic range than the full-length phage. It was also active against *Listeria* spp. However, both CD27L and CD27L₁₋₁₇₉ did not harm the selected gut commensal bacteria[130]. Another endolysin retrieved from *C. difficile* 630 prophage has been described. The lytic activity of full-length PlyCD, and that of a truncated N-terminal containing the catalytic domain PlyCD₁₋₁₇₄ were evaluated. Similar to CD27L, the truncated PlyCD₁₋₁₇₄ exhibited greater lytic activity than its full-length counterpart and also displayed a broader activity range against *C. difficile* strains than the full-length PlyCD. The bactericidal assay demonstrated that PlyCD₁₋₁₇₄

reduced more than 4-log growth of the *C. difficile* hypervirulent MLST2 strains 217B, 615H, and UK1 (027). This result highlighted the potency of PlyCD₁₋₁₇₄ against the crucial clinical strains. Interestingly, PlyCD₁₋₁₇₄ exhibited a synergistic effect with vancomycin pretreatment. The combination treatment between vancomycin and PlyCD₁₋₁₇₄ *in vivo* demonstrated significant inhibition of *C. difficile* growth (> 2-log). Unfortunately, the *in vivo* study of PlyCD₁₋₁₇₄ was unsuccessful due to inconsistent results. *Ex vivo* experiments were conducted using infected mouse cecum and anus as an infecting area. PlyCD₁₋₁₇₄ exhibited 2-log reduction of *C. difficile* cell growth, indicating the activity of PlyCD₁₋₁₇₄ in the gastrointestinal environment[131]. The mechanism by which truncated endolysins exhibit higher efficiency than the wild-type counterpart remains to be explored.

Phage-derived proteins with high specificity to *C. difficile* strains could be developed for targeted therapy. Diffiocin, a contractile R-type phage tail-like bacteriocin, was originally derived from the *C. difficile* strain CD4 (Diffiocin-4). This protein exhibits a higher efficiency when fused with the receptor-binding protein (RBP) of prophage phi027 in the genome of strain R20291 (Av-CD291.1 and Av-CD291.2). Interestingly, avidocin is stably active throughout the mouse gastrointestinal tract when supplied in drinking water containing 4% sucrose and 1% sodium bicarbonate. The specificity of avidocin-CDs was evaluated across *C. difficile* strains, based on which the relationship between RBPs in avidocin-CDs construct and *slpA* allele was concluded[129]. Despite the advances in the knowledge of bacteriophage biology, the use of phage for therapeutic purposes remains much of a challenge. The first challenge is lysogenic conversion, which results in ineffective treatment outcomes. Therefore, the remaining challenge is to identify or engineer the phage to obtain a strictly lytic phage. The subsequent concern is the battle between the host and the phage that occurs during phage infection. Some bacteria naturally mutate and become resistant to phage infection using different mechanisms, *e.g.*, extracellular modification or intracellular modification, as mentioned in a review elsewhere[138]. Still, there is room for lytic phage hunters and phage modification, which are desperately needed. However, to apply this technology effectively in clinical practice, further research is warranted to overcome these limitations.

ILEOSTOMY AND COLONIC LAVAGE ARE RESERVED FOR FULMINANT CDI

At the other end of the spectrum, one alternative treatment is the removal of part of the gut, *i.e.*, colectomy, ileostomy, loop ileostomy, and colonic lavage. This treatment approach is largely reserved for severe and complicated (fulminant) CDI as it is the most invasive treatment. Earlier, colectomy was opted, but it did not improve the clinical outcome, resulting in some mortality[139]. Diverting loop ileostomy and colonic lavage were developed at the Pittsburgh School of Medicine and therefore referred to as the Pittsburgh protocol. This protocol exhibited benefits over conventional colectomy and end ileostomy, which decreased the mortality rate and preserved the colon[140]. We found 2 clinical trials that were terminated due to slow recruitment of participants; hence, there is limited insight into how this method confers benefit to patients with CDI. This indicates to some degree that the current treatment regimen is sufficient to save patients' lives without involving this invasive intervention.

VACCINES ARE THE HOPE FOR CDI CONTROL AND PREVENTION

Current treatment approaches for CDI concentrate primarily on antibiotics. Although antibiotic administration commonly serves as the first-line therapy, prolonged disruption of the normal microbiota can result in recurrent CDI, with incidences of up to 45% after antibiotic therapy[141]. The incidence of healthcare-associated CDI has reduced over time, although there have been recent reports on the growing number of cases of community-associated CDI[142]. Therefore, there exists an urgent need to control and prevent CDI transmission. To date, several preventive remedies for recurrent CDI have been proposed, including antibiotics and FMT. Although their efficacy has been proven, none are recommended by the Infectious Disease Society of America (IDSA), and the protracted efficacy is still questionable. Therefore, vaccines could be a valuable option to serve as long-term prophylaxis for CDI due to their memory function.

Several vaccine candidates have been developed and launched to animal and clinical trials. Currently, a total of 21 clinical trials on *C. difficile* vaccines have been reported, of which 3 were terminated. Most of the vaccine studies have been developed based on 3 formulations, *viz.*, toxoid, recombinant peptide, and surface-associated antigen. In this section, we shall briefly describe each vaccine formulation regarding its development and efficacy in preventing CDI.

Because toxin A and toxin B are key virulence determinants of CDI and associated with the severity of colon damage, they become a remarkable target for vaccine development. The alteration of toxin structure by chemical treatment, thereby inactivating toxicity while preserving its immunogenicity—termed as toxoid—has been developed for over 3 decades. Toxoid-based vaccine use in animal models has demonstrated a satisfactory production level of serum antibody responses against both toxins and a preventive efficacy against a lethal outcome of CDI[143]. The first clinical trial on toxoid-based vaccine in healthy individuals was introduced 20 years ago. It was observed that the majority of study subjects developed a massive level of specific antibodies for both toxins. Although some adverse reactions were documented, the vaccine was demonstrated to be safe and immunogenic in healthy adults[144]. This information paves the way for further development of the next generation of formulated vaccine candidates that are currently under investigation.

The use of a recombinant protein-based design is another approach for vaccine development to avoid residual toxins, which are not completely inactivated by chemical, and also maximizes the protective effect using only the toxin domain responsible for immunogenicity. Furthermore, this genetic modification allows uncomplicated manufacture of vaccine preparations compared with toxoid production. Three functional domains of both toxins, including glucosyl-transferase (GT) and cysteine protease (CP), central translocation (T), and C-terminal receptor-binding domain (RBD), were tested for immunogenic validation. The first study conducted by Lyster *et al*[145] on the use of the RBD of toxin A reported partial protection against CDI and death in a hamster model. The genetic modifications of toxin A RBD were widely investigated by several research groups. These modifications included the use of RBD subdomain, recombinant fusion with other immunogenic proteins, and combination with a mucosal adjuvant[146]. These constructions exhibited strong action by evoking a complete seroconversion for toxin A and preventing fluid secretion and histological changes. Although seroconversion against toxin A was found to be greater than that against toxin B, an optimal vaccine needs to include both toxin A and toxin B fragments to achieve maximum protective efficacy. Therefore, later developments focused on the combination of recombinant peptides with/without immune adjuvants. The fusion peptide, containing fragments of toxin A and toxin B, generates an immune response to both toxins. Complete protection against toxin A was observed at all doses, whereas less immunogenicity toward toxin B was noticed[147]. Co-administration of the combined recombinant protein with the adjuvant also demonstrated satisfactory positive protection, hence this vaccine formulation is currently in phase 1 clinical trial.

To overcome the limitations of previous vaccine candidates related to the prevention of CDI, surface protein antigens have emerged as an alternative target for vaccine development. Several studies have confirmed the induction of immune response during infection against surface layer protein (SLP), including flagella components, adhesin, fibronectin-binding protein, and cysteine protease[148,149]. However, none of the vaccinations provided significant protection in animal models. Furthermore, glycans, the polysaccharide coat on the surface of the bacterium, serve as another target for eliciting specific antibodies. It has been documented that all 3 glycan structures, PSI, PSII and PSIII, conjugated with other immune inducers stimulated specific antibodies, including IgA and IgG, in animal models[150,151]. It was also shown that immune cells can recognize both native and synthesized glycans, supporting the importance of this molecule to be developed as a vaccine and/or a vaccine additive.

There have been several attempts to develop vaccines for CDI. Unfortunately, there is still no approved vaccine to prevent initial and/or recurrent CDI. Nevertheless, there are 2 potential vaccine candidates reaching the final stage of development[152-154]. VLA84, a chimeric protein containing truncated toxin A and toxin B, developed by Valneva Austria GmbH, demonstrated good efficacy in a phase 1 trial[155,156]. It is currently under phase 2 clinical trial (NCT02316470). This clinical phase is a randomized placebo-controlled study of a total of 500 healthy subjects aged > 50 years. The subjects were separated into 4 groups, which individually received different vaccine doses, including VLA84 75 µg without alum, VLA84 200 µg with and without alum, and phosphate-buffered saline as the placebo group. All subjects received 3

doses of vaccination on days 0, 7, and 28. The immunogenicity and safety of VLA84 were evaluated after the last vaccination for up to 6 mo. Based on the primary outcome, it was reported that seroconversion for IgG was ≥ 4 -fold increase for toxin A and toxin B on day 56. However, efficacy and data analysis are yet to be reported.

Pfizer's vaccine has been developed using genetically modified full-length toxin A and toxin B, using a novel detoxification process that preserves the critical epitopes responsible for immunogenicity for maximizing the production of neutralizing antibodies[157,158]. This vaccine entered clinical trials in 2012 and received Fast Track designation from the United States FDA in 2014. The phase 2 clinical trial was completed on patients aged 50–85 years (NCT02117570). The vaccine induced robust immune responses and exerted protective effects in preclinical models. The Pfizer vaccine is currently undergoing phase 3 clinical trials with ≥ 17000 subjects in 23 countries. Subjects aged ≥ 50 years will receive 3-dose vaccinations at months 0, 1, and 6. Volunteers will be followed up for 3 years after the last vaccination. As the trial is ongoing, the results of data analysis from this vaccine are expected in the near future.

Although several vaccines have been developed for decades, aiming to serve as a prophylaxis for CDI, there are concerns and limitations for rapid, long-lasting, and protective immunity. Further efforts are still required to identify optimal dose, dosing schedule, and vaccine formulation, and also to determine potential application for high-risk healthy populations and immunocompromised individuals. Regarding the promising efficacy of a CDI vaccine, if approved, it will provide the primary prevention and reduction of CDI cases worldwide.

CONCLUSION

CDI is a serious healthcare concern as most countries move towards aging societies [159]; *C. difficile* can have maximum impact on this age group. CDI treatment is also threatened by treatment failures, especially recurrent CDI. Therefore, an urgent need exists to develop alternative treatment approaches. Small molecules and natural products have been subjected to the most advanced progress compared with other approaches, followed by an erupting trend of FMT. Both single and combinational therapies appear to be the way forward, such as antibiotic/FMT, antibiotic/antitoxin antibody, and antibiotic/synbiotic. Vaccine development is highly anticipated as the results are extremely promising and would provide a significant tool for CDI prevention and control in community and healthcare settings. Bacteriophage therapy has to overcome the grand challenge before it can be used in clinical practice. These developments are the future of CDI treatment; they require a huge amount of effort and capital; meanwhile, the management of antibiotic use, hygiene precautions and education, and monitoring systems, must be implemented to reduce the incidence of CDI.

ACKNOWLEDGEMENTS

Authors would like to thank Paul Adams for kindly proofreading the final manuscript and the Faculty of Tropical Medicine for subsidizing the English editing service on the first manuscript.

REFERENCES

- 1 Kuiper GA, van Prehn J, Ang W, Kneepkens F, van der Schoor S, de Meij T. *Clostridium difficile* infections in young infants: Case presentations and literature review. *IDCases* 2017; **10**: 7-11 [PMID: 28791215 DOI: 10.1016/j.idcr.2017.07.005]
- 2 Tullus K, Aronsson B, Marcus S, Möllby R. Intestinal colonization with *Clostridium difficile* in infants up to 18 months of age. *Eur J Clin Microbiol Infect Dis* 1989; **8**: 390-393 [PMID: 2502403 DOI: 10.1007/BF01964052]
- 3 Hooks KB, O'Malley MA. Dysbiosis and Its Discontents. *mBio* 2017; **8** [PMID: 29018121 DOI: 10.1128/mBio.01492-17]
- 4 Seekatz AM, Young VB. *Clostridium difficile* and the microbiota. *J Clin Invest* 2014; **124**: 4182-4189 [PMID: 25036699 DOI: 10.1172/JCI72336]
- 5 Chandrasekaran R, Lacy DB. The role of toxins in *Clostridium difficile* infection. *FEMS Microbiol Rev* 2017; **41**: 723-750 [PMID: 29048477 DOI: 10.1093/femsre/fux048]
- 6 Kuehne SA, Collery MM, Kelly ML, Cartman ST, Cockayne A, Minton NP. Importance of toxin A,

- toxin B, and CDT in virulence of an epidemic *Clostridium difficile* strain. *J Infect Dis* 2014; **209**: 83-86 [PMID: [23935202](#) DOI: [10.1093/infdis/jit426](#)]
- 7 **Smits WK**, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. *Clostridium difficile* infection. *Nat Rev Dis Primers* 2016; **2**: 16020 [PMID: [27158839](#) DOI: [10.1038/nrdp.2016.20](#)]
 - 8 **Androga GO**, Hart J, Foster NF, Charles A, Forbes D, Riley TV. Infection with Toxin A-Negative, Toxin B-Negative, Binary Toxin-Positive *Clostridium difficile* in a Young Patient with Ulcerative Colitis. *J Clin Microbiol* 2015; **53**: 3702-3704 [PMID: [26354812](#) DOI: [10.1128/JCM.01810-15](#)]
 - 9 **Eckert C**, Emirian A, Le Monnier A, Cathala L, De Montclos H, Goret J, Berger P, Petit A, De Chevigny A, Jean-Pierre H, Nebbad B, Camiade S, Meckenstock R, Lalande V, Marchandin H, Barbut F. Prevalence and pathogenicity of binary toxin-positive *Clostridium difficile* strains that do not produce toxins A and B. *New Microbes New Infect* 2015; **3**: 12-17 [PMID: [25755885](#) DOI: [10.1016/j.nmni.2014.10.003](#)]
 - 10 **Abt MC**, McKenney PT, Pamer EG. *Clostridium difficile* colitis: pathogenesis and host defence. *Nat Rev Microbiol* 2016; **14**: 609-620 [PMID: [27573580](#) DOI: [10.1038/nrmicro.2016.108](#)]
 - 11 **Poxton IR**, McCoubrey J, Blair G. The pathogenicity of *Clostridium difficile*. *Clin Microbiol Infect* 2001; **7**: 421-427 [PMID: [11591205](#) DOI: [10.1046/j.1198-743x.2001.00287.x](#)]
 - 12 **Suetens C**, Latour K, Kärki T, Ricchizzi E, Kinross P, Moro ML, Jans B, Hopkins S, Hansen S, Lyytikäinen O, Reilly J, Deptula A, Zingg W, Plachouras D, Monnet DL; The Healthcare-Associated Infections Prevalence Study Group. Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017. *Euro Surveill* 2018; **23** [PMID: [30458912](#) DOI: [10.2807/1560-7917.ES.2018.23.46.1800516](#)]
 - 13 **Vardakas KZ**, Trigkidis KK, Boukouvala E, Falagas ME. *Clostridium difficile* infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. *Int J Antimicrob Agents* 2016; **48**: 1-10 [PMID: [27216385](#) DOI: [10.1016/j.ijantimicag.2016.03.008](#)]
 - 14 **O'Grady K**, Knight DR, Riley TV. Antimicrobial resistance in *Clostridioides difficile*. *Eur J Clin Microbiol Infect Dis* 2021 [PMID: [34427801](#) DOI: [10.1007/s10096-021-04311-5](#)]
 - 15 **McDonald LC**, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis* 2018; **66**: e1-e48 [PMID: [29462280](#) DOI: [10.1093/cid/cix1085](#)]
 - 16 **Baur D**, Gladstone BP, Burkert F, Carrara E, Foschi F, Döbele S, Tacconelli E. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and *Clostridium difficile* infection: a systematic review and meta-analysis. *Lancet Infect Dis* 2017; **17**: 990-1001 [PMID: [28629876](#) DOI: [10.1016/S1473-3099\(17\)30325-0](#)]
 - 17 **Negrut N**, Nistor-Cseppento DC, Khan SA, Pantis C, Maghiar TA, Maghiar O, Aleya S, Rus M, Tit DM, Aleya L, Rahdar A, Bungau S. *Clostridium difficile* infection epidemiology over a period of 8 years—a single centre study. *Sustainability* 2020; **12**: 4439 [DOI: [10.3390/su12114439](#)]
 - 18 **Marra AR**, Perencevich EN, Nelson RE, Samore M, Khader K, Chiang HY, Chorazy ML, Herwaldt LA, Diekema DJ, Kuxhausen MF, Blevins A, Ward MA, McDanel JS, Nair R, Balkenende E, Schweizer ML. Incidence and Outcomes Associated With *Clostridium difficile* Infections: A Systematic Review and Meta-analysis. *JAMA Netw Open* 2020; **3**: e1917597 [PMID: [31913488](#) DOI: [10.1001/jamanetworkopen.2019.17597](#)]
 - 19 **Principi N**, Silvestri E, Esposito S. Advantages and Limitations of Bacteriophages for the Treatment of Bacterial Infections. *Front Pharmacol* 2019; **10**: 513 [PMID: [31139086](#) DOI: [10.3389/fphar.2019.00513](#)]
 - 20 **Dedrick RM**, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K, Gilmour KC, Soothill J, Jacobs-Sera D, Schooley RT, Hatfull GF, Spencer H. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant *Mycobacterium abscessus*. *Nat Med* 2019; **25**: 730-733 [PMID: [31068712](#) DOI: [10.1038/s41591-019-0437-z](#)]
 - 21 **Amidon S**, Brown JE, Dave VS. Colon-targeted oral drug delivery systems: design trends and approaches. *AAPS PharmSciTech* 2015; **16**: 731-741 [PMID: [26070545](#) DOI: [10.1208/s12249-015-0350-9](#)]
 - 22 **Jarrad AM**, Karoli T, Blaskovich MA, Lyras D, Cooper MA. *Clostridium difficile* drug pipeline: challenges in discovery and development of new agents. *J Med Chem* 2015; **58**: 5164-5185 [PMID: [25760275](#) DOI: [10.1021/jm5016846](#)]
 - 23 **Petrosillo N**, Granata G, Cataldo MA. Novel Antimicrobials for the Treatment of *Clostridium difficile* Infection. *Front Med (Lausanne)* 2018; **5**: 96 [PMID: [29713630](#) DOI: [10.3389/fmed.2018.00096](#)]
 - 24 **Mendes RE**, Rhomberg PR, Locher HH, Jones RN. Activity of cadazolid against Gram-positive clinical isolates, including linezolid-resistant subsets with defined resistance mechanisms. ICACC; 2013; North Liberty, IA, USA. Available from: <https://www.jmilabs.com/data/posters/ICAAC2013/E-144.PDF>
 - 25 **Chilton CH**, Crowther GS, Baines SD, Todhunter SL, Freeman J, Locher HH, Athanasiou A, Wilcox MH. In vitro activity of cadazolid against clinically relevant *Clostridium difficile* isolates and in an in vitro gut model of *C. difficile* infection. *J Antimicrob Chemother* 2014; **69**: 697-705 [PMID: [24128668](#) DOI: [10.1093/jac/dkt411](#)]

- 26 **Odingo J**, Bailey MA, Files M, Early JV, Alling T, Dennison D, Bowman J, Dalai S, Kumar N, Cramer J, Masquelin T, Hipskind PA, Parish T. In Vitro Evaluation of Novel Nitazoxanide Derivatives against *Mycobacterium tuberculosis*. *ACS Omega* 2017; **2**: 5873-5890 [PMID: [30023755](#) DOI: [10.1021/acsomega.7b00892](#)]
- 27 **Hoffman PS**, Sisson G, Croxen MA, Welch K, Harman WD, Cremades N, Morash MG. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of *Helicobacter pylori*, selected anaerobic bacteria and parasites, and *Campylobacter jejuni*. *Antimicrob Agents Chemother* 2007; **51**: 868-876 [PMID: [17158936](#) DOI: [10.1128/AAC.01159-06](#)]
- 28 **de Carvalho LP**, Darby CM, Rhee KY, Nathan C. Nitazoxanide Disrupts Membrane Potential and Intrabacterial pH Homeostasis of *Mycobacterium tuberculosis*. *ACS Med Chem Lett* 2011; **2**: 849-854 [PMID: [22096616](#) DOI: [10.1021/ml200157f](#)]
- 29 **Rossignol JF**. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. *Antiviral Res* 2014; **110**: 94-103 [PMID: [25108173](#) DOI: [10.1016/j.antiviral.2014.07.014](#)]
- 30 **Stachulski AV**, Tadjanskas J, Pate SL, Rajoli RKR, Aljayyousi G, Pennington SH, Ward SA, Hong WD, Biagini GA, Owen A, Nixon GL, Leung SC, O'Neill PM. Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2? *ACS Infect Dis* 2021; **7**: 1317-1331 [PMID: [33352056](#) DOI: [10.1021/acsinfectdis.0c00478](#)]
- 31 **Musher DM**, Logan N, Bressler AM, Johnson DP, Rossignol JF. Nitazoxanide versus vancomycin in *Clostridium difficile* infection: a randomized, double-blind study. *Clin Infect Dis* 2009; **48**: e41-e46 [PMID: [19133801](#) DOI: [10.1086/596552](#)]
- 32 **Rafiullah F**, Kanwal S, Majeed UM, Korsten MA, Cheema FH, Luthra M, Sohail MR. Successful use of nitazoxanide in the treatment of recurrent *Clostridium difficile* infection. *BMJ Case Rep* 2011; **2011** [PMID: [22674696](#) DOI: [10.1136/bcr.04.2011.4123](#)]
- 33 **Brook I**, Wexler HM, Goldstein EJ. Antianaerobic antimicrobials: spectrum and susceptibility testing. *Clin Microbiol Rev* 2013; **26**: 526-546 [PMID: [23824372](#) DOI: [10.1128/CMR.00086-12](#)]
- 34 **Vickers R**, Robinson N, Best E, Echols R, Tillotson G, Wilcox M. A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for *Clostridium difficile* infections. *BMC Infect Dis* 2015; **15**: 91 [PMID: [25880933](#) DOI: [10.1186/s12879-015-0759-5](#)]
- 35 **Qian X**, Yanagi K, Kane AV, Alden N, Lei M, Snyderman DR, Vickers RJ, Lee K, Thorpe CM. Ridinilazole, a narrow spectrum antibiotic for treatment of *Clostridioides difficile* infection, enhances preservation of microbiota-dependent bile acids. *Am J Physiol Gastrointest Liver Physiol* 2020; **319**: G227-G237 [PMID: [32597706](#) DOI: [10.1152/ajpgi.00046.2020](#)]
- 36 **Bassères E**, Endres BT, Khaleduzzaman M, Miraftabi F, Alam MJ, Vickers RJ, Garey KW. Impact on toxin production and cell morphology in *Clostridium difficile* by ridinilazole (SMT19969), a novel treatment for *C. difficile* infection. *J Antimicrob Chemother* 2016; **71**: 1245-1251 [PMID: [26895772](#) DOI: [10.1093/jac/dkv498](#)]
- 37 **Vickers RJ**, Tillotson GS, Nathan R, Hazan S, Pullman J, Lucasti C, Deck K, Yacyshyn B, Maliakkal B, Pesant Y, Tejura B, Roblin D, Gerding DN, Wilcox MH; CoDIFY study group. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of *Clostridium difficile* infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. *Lancet Infect Dis* 2017; **17**: 735-744 [PMID: [28461207](#) DOI: [10.1016/S1473-3099\(17\)30235-9](#)]
- 38 **Swinney DC**, Anthony J. How were new medicines discovered? *Nat Rev Drug Discov* 2011; **10**: 507-519 [PMID: [21701501](#) DOI: [10.1038/nrd3480](#)]
- 39 **Volochnyuk DM**, Ryabukhin SV, Moroz YS, Savych O, Chuprina A, Horvath D, Zabolotna Y, Varnek A, Judd DB. Evolution of commercially available compounds for HTS. *Drug Discov Today* 2019; **24**: 390-402 [PMID: [30399443](#) DOI: [10.1016/j.drudis.2018.10.016](#)]
- 40 **AbdelKhalek A**, Mohammad H, Mayhoub AS, Seleem MN. Screening for potent and selective anticlostridial leads among FDA-approved drugs. *J Antibiot (Tokyo)* 2020; **73**: 392-409 [PMID: [32132676](#) DOI: [10.1038/s41429-020-0288-3](#)]
- 41 **AbdelKhalek A**, Seleem MN. Repurposing the Veterinary Antiprotozoal Drug Ronidazole for the Treatment of *Clostridioides difficile* Infection. *Int J Antimicrob Agents* 2020; **56**: 106188 [PMID: [33045352](#) DOI: [10.1016/j.ijantimicag.2020.106188](#)]
- 42 **Pushpakom S**, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guillems T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M. Drug repurposing: progress, challenges and recommendations. *Nat Rev Drug Discov* 2019; **18**: 41-58 [PMID: [30310233](#) DOI: [10.1038/nrd.2018.168](#)]
- 43 **Pal R**, Seleem MN. Screening of Natural Products and Approved Oncology Drug Libraries for Activity against *Clostridioides difficile*. *Sci Rep* 2020; **10**: 5966 [PMID: [32249833](#) DOI: [10.1038/s41598-020-63029-0](#)]
- 44 **Fillbrunn A**, Dietz C, Pfeuffer J, Rahn R, Landrum GA, Berthold MR. KNIME for reproducible cross-domain analysis of life science data. *J Biotechnol* 2017; **261**: 149-156 [PMID: [28757290](#) DOI: [10.1016/j.jbiotec.2017.07.028](#)]
- 45 **Beisken S**, Meinel T, Wiswedel B, de Figueiredo LF, Berthold M, Steinbeck C. KNIME-CDK: Workflow-driven cheminformatics. *BMC Bioinformatics* 2013; **14**: 257 [PMID: [24103053](#) DOI: [10.1186/1471-2105-14-257](#)]
- 46 **Mazanetz MP**, Marmon RJ, Reisser CB, Morao I. Drug discovery applications for KNIME: an open source data mining platform. *Curr Top Med Chem* 2012; **12**: 1965-1979 [PMID: [23110532](#) DOI: [10.2174/156802612804910331](#)]

- 47 **Kong KF**, Schnepfer L, Mathee K. Beta-lactam antibiotics: from antibiosis to resistance and bacteriology. *APMIS* 2010; **118**: 1-36 [PMID: [20041868](#) DOI: [10.1111/j.1600-0463.2009.02563.x](#)]
- 48 **Sheehan DJ**, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. *Clin Microbiol Rev* 1999; **12**: 40-79 [PMID: [9880474](#) DOI: [10.1128/CMR.12.1.40](#)]
- 49 **de la Torre BG**, Albericio F. The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules. *Molecules* 2020; **25** [PMID: [32050446](#) DOI: [10.3390/molecules25030745](#)]
- 50 **Palombo EA**. Phytochemicals from traditional medicinal plants used in the treatment of diarrhoea: modes of action and effects on intestinal function. *Phytother Res* 2006; **20**: 717-724 [PMID: [16619336](#) DOI: [10.1002/ptr.1907](#)]
- 51 **Patridge E**, Gareiss P, Kinch MS, Hoyer D. An analysis of FDA-approved drugs: natural products and their derivatives. *Drug Discov Today* 2016; **21**: 204-207 [PMID: [25617672](#) DOI: [10.1016/j.drudis.2015.01.009](#)]
- 52 **Roshan N**, Riley TV, Hammer KA. Antimicrobial activity of natural products against *Clostridium difficile* in vitro. *J Appl Microbiol* 2017; **123**: 92-103 [PMID: [28489336](#) DOI: [10.1111/jam.13486](#)]
- 53 **Perumalsamy H**, Jung MY, Hong SM, Ahn YJ. Growth-Inhibiting and morphostructural effects of constituents identified in *Asarum heterotropoides* root on human intestinal bacteria. *BMC Complement Altern Med* 2013; **13**: 245 [PMID: [24083511](#) DOI: [10.1186/1472-6882-13-245](#)]
- 54 **Fraternali D**, Flamini G, Ricci D. Essential oil composition and antimicrobial activity of *Angelica archangelica* L. (Apiaceae) roots. *J Med Food* 2014; **17**: 1043-1047 [PMID: [24788027](#) DOI: [10.1089/jmf.2013.0012](#)]
- 55 **Cermak P**, Olsovska J, Mikyska A, Dusek M, Kadleckova Z, Vanicek J, Nyc O, Sigler K, Bostikova V, Bostik P. Strong antimicrobial activity of xanthohumol and other derivatives from hops (*Humulus lupulus* L.) on gut anaerobic bacteria. *APMIS* 2017; **125**: 1033-1038 [PMID: [28960474](#) DOI: [10.1111/apm.12747](#)]
- 56 **Canning C**, Sun S, Ji X, Gupta S, Zhou K. Antibacterial and cytotoxic activity of isoprenylated coumarin mamea A/AA isolated from *Mammea africana*. *J Ethnopharmacol* 2013; **147**: 259-262 [PMID: [23466248](#) DOI: [10.1016/j.jep.2013.02.026](#)]
- 57 **Mody D**, Athamneh AIM, Seleem MN. Curcumin: A natural derivative with antibacterial activity against *Clostridium difficile*. *J Glob Antimicrob Resist* 2020; **21**: 154-161 [PMID: [31622683](#) DOI: [10.1016/j.jgar.2019.10.005](#)]
- 58 **Finegold SM**, Summanen PH, Corbett K, Downes J, Henning SM, Li Z. Pomegranate extract exhibits in vitro activity against *Clostridium difficile*. *Nutrition* 2014; **30**: 1210-1212 [PMID: [24976424](#) DOI: [10.1016/j.nut.2014.02.029](#)]
- 59 **de Nova PJG**, Carvajal A, Prieto M, Rubio P. *In vitro* Susceptibility and Evaluation of Techniques for Understanding the Mode of Action of a Promising Non-antibiotic Citrus Fruit Extract Against Several Pathogens. *Front Microbiol* 2019; **10**: 884 [PMID: [31105673](#) DOI: [10.3389/fmicb.2019.00884](#)]
- 60 **Gadhi CA**, Weber M, Mory F, Benharref A, Lion C, Jana M, Lozniewski A. Antibacterial activity of *Aristolochia paucinervis* Pomel. *J Ethnopharmacol* 1999; **67**: 87-92 [PMID: [10616964](#) DOI: [10.1016/s0378-8741\(98\)00212-8](#)]
- 61 **Roshan N**, Riley TV, Knight DR, Steer JH, Hammer KA. Natural products show diverse mechanisms of action against *Clostridium difficile*. *J Appl Microbiol* 2019; **126**: 468-479 [PMID: [30412324](#) DOI: [10.1111/jam.14152](#)]
- 62 **Harnvoravongchai P**, Chankhamhaengdech S, Ounjai P, Singhakaew S, Boonthaworn K, Janvilisri T. Antimicrobial Effect of Asiatic Acid Against *Clostridium difficile* Is Associated With Disruption of Membrane Permeability. *Front Microbiol* 2018; **9**: 2125 [PMID: [30245677](#) DOI: [10.3389/fmicb.2018.02125](#)]
- 63 **Shilling M**, Matt L, Rubin E, Visitacion MP, Haller NA, Grey SF, Woolverton CJ. Antimicrobial effects of virgin coconut oil and its medium-chain fatty acids on *Clostridium difficile*. *J Med Food* 2013; **16**: 1079-1085 [PMID: [24328700](#) DOI: [10.1089/jmf.2012.0303](#)]
- 64 **Blaskovich MAT**, Kavanagh AM, Elliott AG, Zhang B, Ramu S, Amado M, Lowe GJ, Hinton AO, Pham DMT, Zuegg J, Beare N, Quach D, Sharp MD, Pogliano J, Rogers AP, Lyras D, Tan L, West NP, Crawford DW, Peterson ML, Callahan M, Thurn M. The antimicrobial potential of cannabidiol. *Commun Biol* 2021; **4**: 7 [PMID: [33469147](#) DOI: [10.1038/s42003-020-01530-y](#)]
- 65 **Gigli S**, Seguela L, Pesce M, Bruzzese E, D'Alessandro A, Cuomo R, Steardo L, Sarnelli G, Esposito G. Cannabidiol restores intestinal barrier dysfunction and inhibits the apoptotic process induced by *Clostridium difficile* toxin A in Caco-2 cells. *United European Gastroenterol J* 2017; **5**: 1108-1115 [PMID: [29238589](#) DOI: [10.1177/2050640617698622](#)]
- 66 **Adejumo AC**, Bukong TN. Cannabis use and risk of *Clostridioides difficile* infection: Analysis of 59,824 hospitalizations. *Anaerobe* 2020; **61**: 102095 [PMID: [31493498](#) DOI: [10.1016/j.anaerobe.2019.102095](#)]
- 67 **Roshan N**, Riley TV, Hammer KA. Effects of natural products on several stages of the spore cycle of *Clostridium difficile* in vitro. *J Appl Microbiol* 2018; **125**: 710-723 [PMID: [29675852](#) DOI: [10.1111/jam.13889](#)]
- 68 **Mooyottu S**, Flock G, Venkitanarayanan K. Carvacrol reduces *Clostridium difficile* sporulation and spore outgrowth in vitro. *J Med Microbiol* 2017; **66**: 1229-1234 [PMID: [28786786](#) DOI: [10.1099/jmm.0.000515](#)]
- 69 **Yu L**, Palafox-Rosas R, Luna B, She RC. The Bactericidal Activity and Spore Inhibition Effect of

- Manuka Honey against *Clostridioides Difficile*. *Antibiotics (Basel)* 2020; **9** [PMID: 33050172 DOI: 10.3390/antibiotics9100684]
- 70 **Pellissery AJ**, Vinayamohan PG, Venkitanarayanan K. *In vitro* antivirulence activity of baicalin against *Clostridioides difficile*. *J Med Microbiol* 2020; **69**: 631-639 [PMID: 32216868 DOI: 10.1099/jmm.0.001179]
 - 71 **Roshan N**, Riley TV, Knight DR, Hammer KA. Effect of natural products on the production and activity of *Clostridium difficile* toxins in vitro. *Sci Rep* 2018; **8**: 15735 [PMID: 30356168 DOI: 10.1038/s41598-018-33954-2]
 - 72 **Wultańska D**, Piotrowski M, Pituch H. The effect of berberine chloride and/or its combination with vancomycin on the growth, biofilm formation, and motility of *Clostridioides difficile*. *Eur J Clin Microbiol Infect Dis* 2020; **39**: 1391-1399 [PMID: 32140903 DOI: 10.1007/s10096-020-03857-0]
 - 73 **Giles SL**, Laheij RJF. Successful treatment of persistent *Clostridium difficile* infection with manuka honey. *Int J Antimicrob Agents* 2017; **49**: 522-523 [PMID: 28257905 DOI: 10.1016/j.ijantimicag.2017.02.005]
 - 74 **Orth P**, Xiao L, Hernandez LD, Reichert P, Sheth PR, Beaumont M, Yang X, Murgolo N, Ermakov G, DiNunzio E, Racine F, Karczewski J, Secore S, Ingram RN, Mayhood T, Strickland C, Therien AG. Mechanism of action and epitopes of *Clostridium difficile* toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. *J Biol Chem* 2014; **289**: 18008-18021 [PMID: 24821719 DOI: 10.1074/jbc.M114.560748]
 - 75 **Yang Z**, Ramsey J, Hamza T, Zhang Y, Li S, Yfantis HG, Lee D, Hernandez LD, Seghezzi W, Furneisen JM, Davis NM, Therien AG, Feng H. Mechanisms of protection against *Clostridium difficile* infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. *Infect Immun* 2015; **83**: 822-831 [PMID: 25486992 DOI: 10.1128/IAI.02897-14]
 - 76 **Wilcox MH**, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators. Bezlotoxumab for Prevention of Recurrent *Clostridium difficile* Infection. *N Engl J Med* 2017; **376**: 305-317 [PMID: 28121498 DOI: 10.1056/NEJMoa1602615]
 - 77 **Maiti PK**, inventor Immunimed Inc., assignee. Use of polyclonal antibodies against *Clostridium Difficile* for treatment of inflammatory bowel disease. US patent US20180362618A1. 2017. Available from: <https://patents.google.com/patent/US10513552B2/en>
 - 78 **Sponseller JK**, Steele JA, Schmidt DJ, Kim HB, Beamer G, Sun X, Tzipori S. Hyperimmune bovine colostrum as a novel therapy to combat *Clostridium difficile* infection. *J Infect Dis* 2015; **211**: 1334-1341 [PMID: 25381448 DOI: 10.1093/infdis/jiu605]
 - 79 **Heidebrecht HJ**, Weiss WJ, Pulse M, Lange A, Gisch K, Kliem H, Mann S, Pfaffl MW, Kulozik U, von Eichel-Streiber C. Treatment and Prevention of Recurrent *Clostridium difficile* Infection with Functionalized Bovine Antibody-Enriched Whey in a Hamster Primary Infection Model. *Toxins (Basel)* 2019; **11** [PMID: 30736358 DOI: 10.3390/toxins11020098]
 - 80 **Sholeh M**, Krutova M, Forouzes M, Mironov S, Sadeghifard N, Molaeipour L, Maleki A, Kouhsari E. Antimicrobial resistance in *Clostridioides (Clostridium) difficile* derived from humans: a systematic review and meta-analysis. *Antimicrob Resist Infect Control* 2020; **9**: 158 [PMID: 32977835 DOI: 10.1186/s13756-020-00815-5]
 - 81 **Reeves AE**, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB. The interplay between microbiome dynamics and pathogen dynamics in a murine model of *Clostridium difficile* Infection. *Gut Microbes* 2011; **2**: 145-158 [PMID: 21804357 DOI: 10.4161/gmic.2.3.16333]
 - 82 **Gupta S**, Allen-Vercos E, Petrof EO. Fecal microbiota transplantation: in perspective. *Therap Adv Gastroenterol* 2016; **9**: 229-239 [PMID: 26929784 DOI: 10.1177/1756283X15607414]
 - 83 **Sbahi H**, Di Palma JA. Faecal microbiota transplantation: applications and limitations in treating gastrointestinal disorders. *BMJ Open Gastroenterol* 2016; **3**: e000087 [PMID: 27239328 DOI: 10.1136/bmjgast-2016-000087]
 - 84 **Mullish BH**, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, Moore DJ, Colville A, Bhala N, Iqbal TH, Settle C, Kontkowski G, Hart AL, Hawkey PM, Goldenberg SD, Williams HRT. The use of faecal microbiota transplant as treatment for recurrent or refractory *Clostridium difficile* infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. *Gut* 2018; **67**: 1920-1941 [PMID: 30154172 DOI: 10.1136/gutjnl-2018-316818]
 - 85 **Khoruts A**, Staley C, Sadowsky MJ. Faecal microbiota transplantation for *Clostridioides difficile*: mechanisms and pharmacology. *Nat Rev Gastroenterol Hepatol* 2021; **18**: 67-80 [PMID: 32843743 DOI: 10.1038/s41575-020-0350-4]
 - 86 **Segal JP**, Mullish BH, Quraishi MN, Iqbal T, Marchesi JR, Sokol H. Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease. *Therap Adv Gastroenterol* 2020; **13**: 1756284820946904 [PMID: 32952613 DOI: 10.1177/1756284820946904]
 - 87 **van Nood E**, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med* 2013; **368**: 407-415 [PMID: 23323867 DOI: 10.1056/NEJMoa1205037]
 - 88 **Kim KO**, Gluck M. Fecal Microbiota Transplantation: An Update on Clinical Practice. *Clin Endosc* 2019; **52**: 137-143 [PMID: 30909689 DOI: 10.5946/ce.2019.009]
 - 89 **Cammarota G**, Masucci L, Ianaro G, Bibbò S, Dinioi G, Costamagna G, Sanguinetti M, Gasbarrini

- A. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent *Clostridium difficile* infection. *Aliment Pharmacol Ther* 2015; **41**: 835-843 [PMID: 25728808 DOI: 10.1111/apt.13144]
- 90 **Hui W**, Li T, Liu W, Zhou C, Gao F. Fecal microbiota transplantation for treatment of recurrent *C. difficile* infection: An updated randomized controlled trial meta-analysis. *PLoS One* 2019; **14**: e0210016 [PMID: 30673716 DOI: 10.1371/journal.pone.0210016]
 - 91 **Kao D**, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, Chang HJ, Coward S, Goodman KJ, Xu H, Madsen K, Mason A, Wong GK, Jovel J, Patterson J, Louie T. Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent *Clostridium difficile* Infection: A Randomized Clinical Trial. *JAMA* 2017; **318**: 1985-1993 [PMID: 29183074 DOI: 10.1001/jama.2017.17077]
 - 92 **Hamilton MJ**, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. *Gut Microbes* 2013; **4**: 125-135 [PMID: 23333862 DOI: 10.4161/gmic.23571]
 - 93 **Lee CH**, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, Weese JS, Collins S, Moayyedi P, Crowther M, Ropeleski MJ, Jayaratne P, Higgins D, Li Y, Rau NV, Kim PT. Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent *Clostridium difficile* Infection: A Randomized Clinical Trial. *JAMA* 2016; **315**: 142-149 [PMID: 26757463 DOI: 10.1001/jama.2015.18098]
 - 94 **Jiang ZD**, Ajami NJ, Petrosino JF, Jun G, Hanis CL, Shah M, Hochman L, Ankoma-Sey V, DuPont AW, Wong MC, Alexander A, Ke S, DuPont HL. Randomised clinical trial: faecal microbiota transplantation for recurrent *Clostridium difficile* infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. *Aliment Pharmacol Ther* 2017; **45**: 899-908 [PMID: 28220514 DOI: 10.1111/apt.13969]
 - 95 **Agrawal M**, Aroniadis OC, Brandt LJ, Kelly C, Freeman S, Surawicz C, Broussard E, Stollman N, Giovanelli A, Smith B, Yen E, Trivedi A, Hubble L, Kao D, Borody T, Finlayson S, Ray A, Smith R. The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated *Clostridium difficile* Infection in 146 Elderly Individuals. *J Clin Gastroenterol* 2016; **50**: 403-407 [PMID: 26352106 DOI: 10.1097/MCG.0000000000000410]
 - 96 **Fischer M**, Sipe B, Cheng YW, Phelps E, Rogers N, Sagi S, Bohm M, Xu H, Kassam Z. Fecal microbiota transplant in severe and severe-complicated *Clostridium difficile*: A promising treatment approach. *Gut Microbes* 2017; **8**: 289-302 [PMID: 28001467 DOI: 10.1080/19490976.2016.1273998]
 - 97 **DeFilipp Z**, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, Turbett S, Chung RT, Chen YB, Hohmann EL. Drug-Resistant *E. coli* Bacteremia Transmitted by Fecal Microbiota Transplant. *N Engl J Med* 2019; **381**: 2043-2050 [PMID: 31665575 DOI: 10.1056/NEJMoa1910437]
 - 98 **Wilcox MH**, McGovern BH, Hecht GA. The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent *Clostridium difficile* Infection: Current Understanding and Gap Analysis. *Open Forum Infect Dis* 2020; **7**: ofaa114 [PMID: 32405509 DOI: 10.1093/ofid/ofaa114]
 - 99 **Kwak S**, Choi J, Hink T, Reske KA, Blount K, Jones C, Bost MH, Sun X, Burnham CD, Dubberke ER, Dantas G; CDC Prevention Epicenter Program. Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial. *Microbiome* 2020; **8**: 125 [PMID: 32862830 DOI: 10.1186/s40168-020-00907-9]
 - 100 **Ford C**, Litcofsky K, McGovern B, Pardi D, Nathan R, Hansen V, Brennan R, Pullman J, Bernardo P, Tomlinson A, Horgan K, Bryant J, Walsh E, Rodriguez M, Rogalin H, Wang E, Henn M. 1503. Engraftment of investigational microbiome drug, SER-262, in subjects receiving vancomycin is associated with reduced rates of recurrence after primary *Clostridium* infection (CDI). *Open Forum Infect Dis* 2019; **6**: S547-S548 [DOI: 10.1093/ofid/ofz360.1367]
 - 101 **McGovern BH**, Ford CB, Henn MR, Pardi DS, Khanna S, Hohmann EL, O'Brien EJ, Desjardins CA, Bernardo P, Wortman JR, Lombardo MJ, Litcofsky KD, Winkler JA, McChalicher CWJ, Li SS, Tomlinson AD, Nandakumar M, Cook DN, Pomerantz RJ, Aunin JG, Trucksis M. SER-109, an Investigational Microbiome Drug to Reduce Recurrence After *Clostridioides difficile* Infection: Lessons Learned From a Phase 2 Trial. *Clin Infect Dis* 2021; **72**: 2132-2140 [PMID: 32255488 DOI: 10.1093/cid/ciaa387]
 - 102 **Quera R**, Espinoza R, Estay C, Rivera D. Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent *Clostridium difficile* infection. *J Crohns Colitis* 2014; **8**: 252-253 [PMID: 24184170 DOI: 10.1016/j.crohns.2013.10.002]
 - 103 **Vendrik KEW**, Terveer EM, Kuijper EJ, Nooij S, Boeijs-Koppenol E, Sanders IMJG, van Lingen E, Verspaget HW, Berssenbrugge EKL, Keller JJ, van Prehn J; Netherlands Donor Faeces Bank Study Group. Periodic screening of donor faeces with a quarantine period to prevent transmission of multidrug-resistant organisms during faecal microbiota transplantation: a retrospective cohort study. *Lancet Infect Dis* 2021; **21**: 711-721 [PMID: 33275940 DOI: 10.1016/S1473-3099(20)30473-4]
 - 104 **US Food and Drug Administration**. Safety alert regarding use of fecal microbiota for transplantation and additional safety protections pertaining to SARS-CoV-2 and COVID-19. 2020. Available from: <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/safety-alert-regarding-use-fecal-microbiota-transplantation-and-additional-safety-protections>
 - 105 **Joint FAO/WHO**. Guidelines for the evaluation of probiotics in food. 2002. Available from:

- https://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf
- 106 **Hill C**, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol* 2014; **11**: 506-514 [PMID: [24912386](#) DOI: [10.1038/nrgastro.2014.66](#)]
 - 107 **Hudson LE**, Anderson SE, Corbett AH, Lamb TJ. Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. *Clin Microbiol Rev* 2017; **30**: 191-231 [PMID: [27856521](#) DOI: [10.1128/CMR.00049-16](#)]
 - 108 **Mills JP**, Rao K, Young VB. Probiotics for prevention of Clostridium difficile infection. *Curr Opin Gastroenterol* 2018; **34**: 3-10 [PMID: [29189354](#) DOI: [10.1097/MOG.0000000000000410](#)]
 - 109 **McFarland LV**, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z. A randomized placebo-controlled trial of *Saccharomyces boulardii* in combination with standard antibiotics for Clostridium difficile disease. *JAMA* 1994; **271**: 1913-1918 [PMID: [8201735](#)]
 - 110 **Gorbach SL**, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. *Lancet* 1987; **2**: 1519 [PMID: [2892070](#) DOI: [10.1016/s0140-6736\(87\)92646-8](#)]
 - 111 **Pace F**, Pace M, Quartarone G. Probiotics in digestive diseases: focus on Lactobacillus GG. *Minerva Gastroenterol Dietol* 2015; **61**: 273-292 [PMID: [26657927](#)]
 - 112 **Cameron D**, Hock QS, Kadim M, Mohan N, Ryoo E, Sandhu B, Yamashiro Y, Jie C, Hoekstra H, Guarino A. Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. *World J Gastroenterol* 2017; **23**: 7952-7964 [PMID: [29259371](#) DOI: [10.3748/wjg.v23.i45.7952](#)]
 - 113 **Valdés-Varela L**, Gueimonde M, Ruas-Madiedo P. Probiotics for Prevention and Treatment of Clostridium difficile Infection. *Adv Exp Med Biol* 2018; **1050**: 161-176 [PMID: [29383669](#) DOI: [10.1007/978-3-319-72799-8_10](#)]
 - 114 **McFarland LV**, Ship N, Auclair J, Millette M. Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence. *J Hosp Infect* 2018; **99**: 443-452 [PMID: [29702133](#) DOI: [10.1016/j.jhin.2018.04.017](#)]
 - 115 **Hickson M**, D'Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C, Bulpitt CJ. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. *BMJ* 2007; **335**: 80 [PMID: [17604300](#) DOI: [10.1136/bmj.39231.599815.55](#)]
 - 116 **Gao XW**, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. *Am J Gastroenterol* 2010; **105**: 1636-1641 [PMID: [20145608](#) DOI: [10.1038/ajg.2010.11](#)]
 - 117 **Barker AK**, Duster M, Valentine S, Hess T, Archbald-Pannone L, Guerrant R, Safdar N. A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO). *J Antimicrob Chemother* 2017; **72**: 3177-3180 [PMID: [28961980](#) DOI: [10.1093/jac/dkx254](#)]
 - 118 **Zmora N**, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashariades S, Kotler E, Zur M, Regev-Lehavi D, Brik RB, Federici S, Cohen Y, Linevsky R, Rothschild D, Moor AE, Ben-Moshe S, Harmelin A, Itzkovitz S, Maharshak N, Shibolet O, Shapiro H, Pevsner-Fischer M, Sharon I, Halpern Z, Segal E, Elinav E. Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. *Cell* 2018; **174**: 1388-1405.e21 [PMID: [30193112](#) DOI: [10.1016/j.cell.2018.08.041](#)]
 - 119 **Rothschild D**, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, Costea PI, Godneva A, Kalka IN, Bar N, Shilo S, Lador D, Vila AV, Zmora N, Pevsner-Fischer M, Israeli D, Kosower N, Malka G, Wolf BC, Avnit-Sagi T, Lotan-Pompan M, Weinberger A, Halpern Z, Carmi S, Fu J, Wijmenga C, Zhernakova A, Elinav E, Segal E. Environment dominates over host genetics in shaping human gut microbiota. *Nature* 2018; **555**: 210-215 [PMID: [29489753](#) DOI: [10.1038/nature25973](#)]
 - 120 **So D**, Whelan K, Rossi M, Morrison M, Holtmann G, Kelly JT, Shanahan ER, Staudacher HM, Campbell KL. Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis. *Am J Clin Nutr* 2018; **107**: 965-983 [PMID: [29757343](#) DOI: [10.1093/ajcn/nqy041](#)]
 - 121 **Gibson GR**, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, Verbeke K, Reid G. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 491-502 [PMID: [28611480](#) DOI: [10.1038/nrgastro.2017.75](#)]
 - 122 **Rätsep M**, Kõljalg S, Sepp E, Smidt I, Truusalu K, Songisepp E, Stsepetova J, Naaber P, Mikelsaar RH, Mikelsaar M. A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection. *Anaerobe* 2017; **47**: 94-103 [PMID: [28465256](#) DOI: [10.1016/j.anaerobe.2017.03.019](#)]
 - 123 **Sell TL**, Schaberg DR, Fekety FR. Bacteriophage and bacteriocin typing scheme for Clostridium difficile. *J Clin Microbiol* 1983; **17**: 1148-1152 [PMID: [6874905](#) DOI: [10.1128/JCM.17.6.1148-1152.1983](#)]

- 124 **Fortier LC**, Moineau S. Morphological and genetic diversity of temperate phages in *Clostridium difficile*. *Appl Environ Microbiol* 2007; **73**: 7358-7366 [PMID: [17890338](#) DOI: [10.1128/AEM.00582-07](#)]
- 125 **Mayer MJ**, Narbad A, Gasson MJ. Molecular characterization of a *Clostridium difficile* bacteriophage and its cloned biologically active endolysin. *J Bacteriol* 2008; **190**: 6734-6740 [PMID: [18708505](#) DOI: [10.1128/JB.00686-08](#)]
- 126 **Fortier LC**. Bacteriophages Contribute to Shaping *Clostridioides (Clostridium) difficile* Species. *Front Microbiol* 2018; **9**: 2033 [PMID: [30233520](#) DOI: [10.3389/fmicb.2018.02033](#)]
- 127 **Li T**, Zhang Y, Dong K, Kuo CJ, Li C, Zhu YQ, Qin J, Li QT, Chang YF, Guo X, Zhu Y. Isolation and Characterization of the Novel Phage JD032 and Global Transcriptomic Response during JD032 Infection of *Clostridioides difficile* Ribotype 078. *mSystems* 2020; **5** [PMID: [32371470](#) DOI: [10.1128/mSystems.00017-20](#)]
- 128 **Drulis-Kawa Z**, Majkowska-Skrobek G, Maciejewska B. Bacteriophages and phage-derived proteins--application approaches. *Curr Med Chem* 2015; **22**: 1757-1773 [PMID: [25666799](#) DOI: [10.2174/0929867322666150209152851](#)]
- 129 **Gebhart D**, Lok S, Clare S, Tomas M, Stares M, Scholl D, Donskey CJ, Lawley TD, Govoni GR. A modified R-type bacteriocin specifically targeting *Clostridium difficile* prevents colonization of mice without affecting gut microbiota diversity. *mBio* 2015; **6** [PMID: [25805733](#) DOI: [10.1128/mBio.02368-14](#)]
- 130 **Mayer MJ**, Garefalaki V, Spoerl R, Narbad A, Meijers R. Structure-based modification of a *Clostridium difficile*-targeting endolysin affects activity and host range. *J Bacteriol* 2011; **193**: 5477-5486 [PMID: [21803993](#) DOI: [10.1128/JB.00439-11](#)]
- 131 **Wang Q**, Euler CW, Delaune A, Fischetti VA. Using a Novel Lysin To Help Control *Clostridium difficile* Infections. *Antimicrob Agents Chemother* 2015; **59**: 7447-7457 [PMID: [26392484](#) DOI: [10.1128/AAC.01357-15](#)]
- 132 **Meador E**, Mayer MJ, Steverding D, Carding SR, Narbad A. Evaluation of bacteriophage therapy to control *Clostridium difficile* and toxin production in an in vitro human colon model system. *Anaerobe* 2013; **22**: 25-30 [PMID: [23685029](#) DOI: [10.1016/j.anaerobe.2013.05.001](#)]
- 133 **Loc-Carrillo C**, Abedon ST. Pros and cons of phage therapy. *Bacteriophage* 2011; **1**: 111-114 [PMID: [22334867](#) DOI: [10.4161/bact.1.2.14590](#)]
- 134 **Nale JY**, Spencer J, Hargreaves KR, Buckley AM, Trzepiński P, Douce GR, Clokie MR. Bacteriophage Combinations Significantly Reduce *Clostridium difficile* Growth In Vitro and Proliferation In Vivo. *Antimicrob Agents Chemother* 2016; **60**: 968-981 [PMID: [26643348](#) DOI: [10.1128/AAC.01774-15](#)]
- 135 **Selle K**, Fletcher JR, Tuson H, Schmitt DS, McMillan L, Vridhambal GS, Rivera AJ, Montgomery SA, Fortier LC, Barrangou R, Theriot CM, Ousterout DG. *In Vivo* Targeting of *Clostridioides difficile* Using Phage-Delivered CRISPR-Cas3 Antimicrobials. *mBio* 2020; **11** [PMID: [32156803](#) DOI: [10.1128/mBio.00019-20](#)]
- 136 **Nale JY**, Redgwell TA, Millard A, Clokie MRJ. Efficacy of an Optimised Bacteriophage Cocktail to Clear *Clostridium difficile* in a Batch Fermentation Model. *Antibiotics (Basel)* 2018; **7** [PMID: [29438355](#) DOI: [10.3390/antibiotics7010013](#)]
- 137 **Shan J**, Ramachandran A, Thanki AM, Vukusic FBI, Barylski J, Clokie MRJ. Bacteriophages are more virulent to bacteria with human cells than they are in bacterial culture; insights from HT-29 cells. *Sci Rep* 2018; **8**: 5091 [PMID: [29572482](#) DOI: [10.1038/s41598-018-23418-y](#)]
- 138 **Cafilisch KM**, Suh GA, Patel R. Biological challenges of phage therapy and proposed solutions: a literature review. *Expert Rev Anti Infect Ther* 2019; **17**: 1011-1041 [PMID: [31735090](#) DOI: [10.1080/14787210.2019.1694905](#)]
- 139 **Hall JF**, Berger D. Outcome of colectomy for *Clostridium difficile* colitis: a plea for early surgical management. *Am J Surg* 2008; **196**: 384-388 [PMID: [18519126](#) DOI: [10.1016/j.amjsurg.2007.11.017](#)]
- 140 **Neal MD**, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated *Clostridium difficile* associated disease. *Ann Surg* 2011; **254**: 423-7; discussion 427 [PMID: [21865943](#) DOI: [10.1097/SLA.0b013e31822ade48](#)]
- 141 **McFarland LV**, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent *Clostridium difficile* disease. *Am J Gastroenterol* 2002; **97**: 1769-1775 [PMID: [12135033](#) DOI: [10.1111/j.1572-0241.2002.05839.x](#)]
- 142 **Popovich KJ**, Calfee DP, Patel PK, Lassiter S, Rolle AJ, Hung L, Saint S, Chopra V. The Centers for Disease Control and Prevention STRIVE Initiative: Construction of a National Program to Reduce Health Care-Associated Infections at the Local Level. *Ann Intern Med* 2019; **171**: S2-S6 [PMID: [31569228](#) DOI: [10.7326/M18-3529](#)]
- 143 **Anosova NG**, Brown AM, Li L, Liu N, Cole LE, Zhang J, Mehta H, Kleanthous H. Systemic antibody responses induced by a two-component *Clostridium difficile* toxoid vaccine protect against *C. difficile*-associated disease in hamsters. *J Med Microbiol* 2013; **62**: 1394-1404 [PMID: [23518659](#) DOI: [10.1099/jmm.0.056796-0](#)]
- 144 **Sehgal K**, Khanna S. Immune response against *Clostridioides difficile* and translation to therapy. *Therap Adv Gastroenterol* 2021; **14**: 17562848211014817 [PMID: [33995585](#) DOI: [10.1177/17562848211014817](#)]
- 145 **Lyerly DM**, Johnson JL, Frey SM, Wilkins TD. Vaccination against lethal *Clostridium difficile*

- enterocolitis with a nontoxic recombinant peptide of toxin A. *Curr Microbiol* 1990; **21**: 29-32 [DOI: [10.1007/BF02090096](https://doi.org/10.1007/BF02090096)]
- 146 **Ward SJ**, Douce G, Dougan G, Wren BW. Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from *Clostridium difficile*. *Infect Immun* 1999; **67**: 5124-5132 [PMID: [10496886](https://pubmed.ncbi.nlm.nih.gov/10496886/) DOI: [10.1128/IAI.67.10.5124-5132.1999](https://doi.org/10.1128/IAI.67.10.5124-5132.1999)]
 - 147 **Ghose C**, Verhagen JM, Chen X, Yu J, Huang Y, Chenesseau O, Kelly CP, Ho DD. Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of *Clostridium difficile* toxins A and B and *Salmonella enterica* serovar typhimurium flagellin in a mouse model of *Clostridium difficile* disease. *Infect Immun* 2013; **81**: 2190-2196 [PMID: [23545305](https://pubmed.ncbi.nlm.nih.gov/23545305/) DOI: [10.1128/IAI.01074-12](https://doi.org/10.1128/IAI.01074-12)]
 - 148 **Péchiné S**, Janoir C, Collignon A. Variability of *Clostridium difficile* surface proteins and specific serum antibody response in patients with *Clostridium difficile*-associated disease. *J Clin Microbiol* 2005; **43**: 5018-5025 [PMID: [16207956](https://pubmed.ncbi.nlm.nih.gov/16207956/) DOI: [10.1128/JCM.43.10.5018-5025.2005](https://doi.org/10.1128/JCM.43.10.5018-5025.2005)]
 - 149 **Wright A**, Drudy D, Kyne L, Brown K, Fairweather NF. Immunoreactive cell wall proteins of *Clostridium difficile* identified by human sera. *J Med Microbiol* 2008; **57**: 750-756 [PMID: [18480333](https://pubmed.ncbi.nlm.nih.gov/18480333/) DOI: [10.1099/jmm.0.47532-0](https://doi.org/10.1099/jmm.0.47532-0)]
 - 150 **Adamo R**, Romano MR, Berti F, Leuzzi R, Tontini M, Danieli E, Cappelletti E, Cakici OS, Swennen E, Pinto V, Brogioni B, Proietti D, Galeotti CL, Lay L, Monteiro MA, Scarselli M, Costantino P. Phosphorylation of the synthetic hexasaccharide repeating unit is essential for the induction of antibodies to *Clostridium difficile* PSII cell wall polysaccharide. *ACS Chem Biol* 2012; **7**: 1420-1428 [PMID: [22620974](https://pubmed.ncbi.nlm.nih.gov/22620974/) DOI: [10.1021/cb300221f](https://doi.org/10.1021/cb300221f)]
 - 151 **Monteiro MA**, Ma Z, Bertolo L, Jiao Y, Arroyo L, Hodgins D, Mallozzi M, Vedantam G, Sagermann M, Sundsmo J, Chow H. Carbohydrate-based *Clostridium difficile* vaccines. *Expert Rev Vaccines* 2013; **12**: 421-431 [PMID: [23560922](https://pubmed.ncbi.nlm.nih.gov/23560922/) DOI: [10.1586/erv.13.9](https://doi.org/10.1586/erv.13.9)]
 - 152 **Legenza LM**, Barnett SG, Rose WE. Vaccines in development for the primary prevention of *Clostridium difficile* infection. *J Am Pharm Assoc (2003)* 2017; **57**: 547-549 [PMID: [28712463](https://pubmed.ncbi.nlm.nih.gov/28712463/) DOI: [10.1016/j.japh.2017.06.007](https://doi.org/10.1016/j.japh.2017.06.007)]
 - 153 **Leuzzi R**, Adamo R, Scarselli M. Vaccines against *Clostridium difficile*. *Hum Vaccin Immunother* 2014; **10**: 1466-1477 [PMID: [24637887](https://pubmed.ncbi.nlm.nih.gov/24637887/) DOI: [10.4161/hv.28428](https://doi.org/10.4161/hv.28428)]
 - 154 **Riley TV**, Lyras D, Douce GR. Status of vaccine research and development for *Clostridium difficile*. *Vaccine* 2019; **37**: 7300-7306 [PMID: [30902484](https://pubmed.ncbi.nlm.nih.gov/30902484/) DOI: [10.1016/j.vaccine.2019.02.052](https://doi.org/10.1016/j.vaccine.2019.02.052)]
 - 155 **Bézay N**, Ayad A, Dubischar K, Firbas C, Hochreiter R, Kiermayr S, Kiss I, Pinl F, Jilma B, Westritschnig K. Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against *Clostridium difficile*, in healthy volunteers. *Vaccine* 2016; **34**: 2585-2592 [PMID: [27079932](https://pubmed.ncbi.nlm.nih.gov/27079932/) DOI: [10.1016/j.vaccine.2016.03.098](https://doi.org/10.1016/j.vaccine.2016.03.098)]
 - 156 **Tian JH**, Glenn G, Flyer D, Zhou B, Liu Y, Sullivan E, Wu H, Cummings JF, Ellingsworth L, Smith G. *Clostridium difficile* chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models. *Vaccine* 2017; **35**: 4079-4087 [PMID: [28669616](https://pubmed.ncbi.nlm.nih.gov/28669616/) DOI: [10.1016/j.vaccine.2017.06.062](https://doi.org/10.1016/j.vaccine.2017.06.062)]
 - 157 **Donald RGK**, Flint M, Kalyan N, Johnson E, Witko SE, Kotash C, Zhao P, Megati S, Yurgelonis I, Lee PK, Matsuka YV, Severina E, Deatly A, Sidhu M, Jansen KU, Minton NP, Anderson AS. A novel approach to generate a recombinant toxoid vaccine against *Clostridium difficile*. *Microbiology (Reading)* 2013; **159**: 1254-1266 [PMID: [23629868](https://pubmed.ncbi.nlm.nih.gov/23629868/) DOI: [10.1099/mic.0.066712-0](https://doi.org/10.1099/mic.0.066712-0)]
 - 158 **Vidunas E**, Mathews A, Weaver M, Cai P, Koh EH, Patel-Brown S, Yuan H, Zheng ZR, Carriere M, Johnson JE, Lotvin J, Moran J. Production and Characterization of Chemically Inactivated Genetically Engineered *Clostridium difficile* Toxoids. *J Pharm Sci* 2016; **105**: 2032-2041 [PMID: [27233688](https://pubmed.ncbi.nlm.nih.gov/27233688/) DOI: [10.1016/j.xphs.2016.04.017](https://doi.org/10.1016/j.xphs.2016.04.017)]
 - 159 **United Nations**, Department of Economic and Social Affairs, Population Division. World population aging 2019: Highlight. 2019. Available from: <https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Report.pdf>



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

